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Abstract 
 
Since time immemorial certain plants and/or extracts thereof have been used for the 
treatment of various diseases. The utility of such materials is normally attributed to the 
specific chemical components within the source plants. For this reason, chemists have 
sought to isolate the active principals for evaluation and the more efficacious ones have 
been the subject of synthetic studies. Since biological activity is normally embodied in 
one but not the other enantiomeric form of homochiral natural products, the selective 
synthesis of such species has become an important aspect of such endeavours. The use of 
chirons for such purposes has often provided a very effective means of obtaining a given 
enantiomeric form of the target compound. Since various enantiomerically pure cis-1,2-
dihydrocatechols (such as compounds 3c and 3d) have become available in large quantity 
via the whole-cell biotransformation of certain halogenated arenes they have become 
particularly important starting materials in natural product synthesis. This is all the more 
so with the recognition that the “hidden symmetry elements” embodied within such 
chirons can allow for the generation of either enantiomeric form of a target compound 
from a single enantiomeric form of such starting materials, a process sometimes termed 
enantiodivergent synthesis. In this thesis, approaches to the syntheses of the biologically 
significant systems such as ent-kirkamide, (+)-lycorine, and (+)-narseronine are 
described by using enzymatically generated cis-1,2-dihydrocatechols.  
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Specifically, the first chapter of this thesis analyses the current state-of-play with respect 
to the generation of cis-1,2-dihydrocatechols of the general form 3 and their application 
in chemical synthesis, especially as this applies to the assembly of biologically active 
natural products and related systems.  
 
The approaches employed in establishing a near-to-complete total synthesis of ent-
kirkamide from (1S,2S)-3-bromocyclohexa-3,5-diene-1,2-diol (3c) and its iodo-
counterpart 3d are described in Chapter Two. This is preceded by a commentary on the 
origins, structural elucidation and biological properties of the natural product (viz. 
kirkamide) along with a description of the only total synthesis of this compound reported 
to date. 
 
A chemoenzymatic approach to the total synthesis of (+)-lycorine using (1S,2S)-3-
bromocyclohexa-3,5-diene-1,2-diol (3c) as starting material is discussed in the third 
chapter. This is preceded by a description of the synthetic approaches (reported by others) 
to either the (+)- or (–)-form of lycorine. 
 
The work reported in the fourth chapter on the successful synthesis of (+)-narseronine 
from the bromobenzene-derived metabolite 3c serves to emphasize the utility of cis-1,2-
dihydrocatechols as chiral building blocks. Since earlier work within the Banwell Group 
had resulted in the development of a synthesis of (–)-narseronine from the same starting 
material, the present work serves to emphasize the capacity for undertaking 
enantiodivergent syntheses using the “pseudo-symmetric” cis-1,2-dihydrocatechol 3c as 
starting material. 
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The final chapter details all the experimental work that were undertaken/accumulated by 
the author as the underpinning evidence for the claims made in the earlier parts of the 
thesis. The spectral data sets arising from the experimental work are also provided in this 
chapter 
 
The Appendices contain a summary of the reaction schemes associated with the author’s 
efforts to obtain the aforementioned natural products (or their enantiomers) as well as all 
the X-ray crystallographic data generated during the course of these studies.  
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1.1 The Synthesis of Natural Products as a Scientific Endeavour 
 
The 2015 Nobel Prize in Physiology and Medicine was granted, jointly, to William C. 
Campbell and Satoshi Ōmura "for their discoveries concerning a novel therapy against 
infections caused by roundworm parasites" and to Youyou Tu "for her discoveries 
concerning a novel therapy against Malaria". This award highlights the capacity of 
natural products to provide privileged structures/molecular scaffolds that can be 
developed as medicines or agrochemicals.[1] Indeed, a recent survey by Newman and 
Cragg[2] that analysed 1562 approved therapeutic agents produced (and marketed) over 
the last 30 years (see Chart 1-1), revealed the importance of natural products in the drug 
discovery and development process. Specifically, it showed that 5% of the registered 
drugs were from natural sources, comprising so-called botanical drugs (1%) such as 
Chinese/Indian traditional herbal medicines and unaltered natural products (4%). More 
significantly, natural product-based pharmaceuticals that had been produced by chemical 
synthesis (31%), synthetically generated natural product derivatives (21%) and natural 
product analogues (also produced synthetically) (10%) contributed to more than half of 
the total registered drugs. The remaining 22% of the suite of 1562 approved drugs were 
comprised of biological macromolecules and vaccines. 
 
This situation highlights the powerful interplay between the study of natural products and 
chemical synthesis with each inspiring the other in terms of assisting with the drug 
development process. Arguably, then, there is a continuing need for at least some of those 
undertaking studies in chemical synthesis to focus on natural product targets as a means 
for addressing issues of supply (in instances where the natural products are only available 
in very limited amounts from nature) or obtaining structural variants (especially in ways 
not available through manipulation of the natural product itself). A further challenge 
Chapter One 
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associated with such endeavours is the need to develop environmentally sensitive 
synthetic routes to the target compounds, a matter that can sometimes be addressed 
through the proper selection of starting materials, especially abundant and homochiral 
ones. In this connection, cis-1,2-dihydrocatechols are emerging as important new chirons 
(chiral building blocks) by virtue of their ready and enantioselective production at large 
scales through the whole-cell biotransformation of the corresponding (and readily 
available) aromatic compounds. Indeed, they have already been shown to serve as highly 
versatile starting materials in the preparation of a wide range of natural products.[2] The 
following sections detail the production of such metabolites and previous applications of 
these in the total synthesis of a wide range of natural products and natural product 
scaffolds. 
 
______________________________________________________________________ 
 
B          biological macromolecule N unaltered natural product 
 
NB botanical drug (defined mixture) ND natural product derivative 
 
S synthetic drug                                    S*             synthetic drug (NP pharmacophore) 
 
V vaccine                                               S*/N
M     
mimic of natural product 
 
 
Chart 1-1. 1562 newly approved drugs during 1981-2014[2] 
______________________________________________________________________ 
 
21% 1% 
4% 
16% 
6% 10% 4% 
11% 
27% 
ND = 21%, 320 
NB = 1%, 9 
N = 4%, 67 
B = 16%, 250 
V = 6%, 101
S*/NM = 10%, 162 
S* = 4%, 61 
S/NM = 11%, 172 
S = 27%, 420 
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1.2 The Microbial Conversion of Arenes into cis-1,2-Dihydrocatechols 
 
The term “fermentation” derives from the Latin word fermentum and refers to an 
anaerobic metabolic process in which carbohydrates are converted into alcohol or organic 
acids using microorganisms, e.g. yeasts or bacteria. Louis Pasteur[3] was the first 
zymologist (a person skilled in the fermentation of liquors) to cultivate the yeast now 
known to be responsible for certain key fermentation processes. Historically, 
fermentation was recognized as a mode of anaerobic respiration and initially used for the 
preservation and modification of certain foodstuffs. From the 19th century onwards, its 
uses were refined and/or extended to the production of cheese, vinegar, soy sauce, wine, 
beer and other beverages.[4] Metabolites from such processes were used to create specific 
aromas, colors, tastes, textures and/or flavors, especially ones with nutritional values.[4] 
By the early 1900’s fermentation products such as gallic and lactic acids were being 
generated to serve as food preservatives and in 1907 Eduard Buchner was awarded the 
Nobel Prize in Chemistry for his discovery and exploitation of “cell-free fermentation”[5] 
that not only started a new age of fermentation but also underpinned the industrial 
production of key commodity chemicals such as acetone, butanol and butanediol as well 
as organic acid products such as citric and gluconic acids.[5] The development of 
fermentation methods for the preparation of antibiotics such as penicillin followed during 
the later stages of World War II. Nowadays, a diverse range of key chemicals is produced 
industrially by fermentation, including pharmaceuticals, enzymes, amino acids, vitamins, 
antibiotics, alcohols and industrial solvents. In addition, microbially-derived pesticides 
have dramatically increased agricultural productivity while simultaneously reducing the 
environmental burden associated with their application.[4] From a chemist’s perspective, 
certain enantiomerically pure fermentation products (or metabolites) have come to be 
recognized as potentially valuable starting materials for the chemical synthesis of target 
Chapter One 
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compounds in homochiral form. cis-1,2-Dihydrocatechols (c-DHCs) produced through 
the whole-cell cis-1,2-dihydroxylation of the corresponding aromatics are one such group 
of metabolites and they are now discussed in some detail because of their relevance to the 
research reported in the body of this thesis. 
 
The bio-conversion of arenes into cis-1,2-dihydrocatechols is a matter that has attracted 
considerable attention,[6-10] especially in recent times. The oxidative degradation of 
aromatic compounds by micro-organisms was a topic first studied by Sŏhngen et al. in 
the early parts of the 20th century[11] but it was not until the 1960’s that Gibson and co-
workers reported[12,13] on the metabolism of aromatics by Pseudomonas putida (P. 
putida)-type bacteria and so revealing some of mechanistic details[14] (see Scheme 1-1) 
of these types of processes.  
______________________________________________________________________ 
 
Scheme 1-1. Biodegradation of toluene into c-DHC 3b and the structural confirmation of the 
latter via crystalline derivative 7 
______________________________________________________________________ 
 
Specifically, the Gibson Group’s isotopic labeling studies established that the 
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biotransformation of toluene (1) by the mutant Pseudomonas putida 39/D takes place in 
a manner distinct from that observed in mammalian systems[15-19] and wherein both atoms 
of a given molecule of 18O2 are incorporated, probably through a transition state of the 
general form 2, into the primary metabolite 3b. This is then “processed” further, through 
the action of a dehydrogenase enzyme, to yield catechol 4. Ultimately, water and carbon 
dioxide are produced along with various other small carbon-containing metabolites, such 
as muconic, pyruvic, and acetic acid. 
 
Various efforts[20-25] were made to assign the absolute configuration of the homochiral 
cis-1,2-dihydrocatechols produced through the metabolism of, for example, toluene and 
chlorobenzene. Eventually, and as shown in Scheme 1-1, the metabolite 3b was 
acetylated to give di-ester 5 that could itself be engaged in a facially selective hetero-
Diels-Alder reaction with the potent and brominated dienophile 6 to afford adduct 7 that 
was subjected to single-crystal X-ray analysis.[24,26] This work served as the basis for the 
initial assignment of the absolute stereochemistry of a range of related metabolites. In 
many instances these initial assignments have been confirmed through various chemical 
correlation studies, including ones involving their transformation into natural products of 
the defined absolute configuration.  
 
Accompanying such studies were ones demonstrating that a wide range of aromatic 
substrates[18,27,29-32] could be biotransformed by dioxygenase enzymes. Furthermore, 
mutant forms of the original/wild-type bacteria[29,33-35] produced through, for example, 
directed evolution techniques, were shown to effect related conversions of a suite of 
previously metabolically-resistant aromatics.[36,37] By this means, an impressive range of 
essentially enantiopure cis-1,2-dihydrocatechols (c-DHCs),[38] including those shown in 
Figure 1-1, has now become available to the synthetic chemist.  
Chapter One 
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Figure 1-1. Examples of readily available cis-1,2-dihydrocatechols and related species available 
through whole-cell biotransformation of the corresponding aromatic substrates 
______________________________________________________________________ 
1.3 Reactive Sites within (1S,2S)-3-Bromocyclohexa-3,5-diene-1,2-diol (3c) and 
Their Exploitation in Chemical Synthesis	
 
The homochiral nature and ready accessibility of the metabolically-derived cis-1,2-
dihydrocatechols prompted organic chemists to consider using them as starting materials 
in chemical synthesis, albeit only a remarkably long time after their structures were first 
established. In fact, it was only in 1987[39a] that Ley first pointed out the considerable 
potential of cis-1,2-dihydrocatechols of this type in organic synthesis. Subsequent work 
carried out by Ley,[39] Banwell,[40] Carless,[41] and Hudlicky,[42] among others, served to 
reinforce this proposition and also led to the recognition that the brominated system 3c, 
for example, was capable of engaging in some rather specific and especially useful 
transformations, some of which are summarized in Figure 1-2.[40r] Thus, typical 
manipulations of this compound include regioselective electrophilic epoxidation,[40l,40k,43-
48] dihydroxylation,[42e] hydrogenation,[49] aziridination,[50-53] halogenation[54] and [2+2] 
cycloaddition reactions at the more electron-rich (non-halogenated) C5-C6 double 
bond.[55] The stereoselectivity of these processes is often strongly influenced by the 
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presence of the adjacent stereogenic centers (at C1 and C2) while the ring-cleavage of the 
product epoxides is, for example, influenced by the presence of the remaining C3-C4 
double bond.[56-58] The bromo-olefin is amenable to a wide range of cross-coupling 
reactions[59-64] while the conjugated diene moiety can participate, as the 4p-addend, in a 
significant range of cycloaddition reactions.[58,60,61,65-70] Of course, the hydroxyl groups 
themselves are also capable of manipulations in various ways, either individually or 
together (and most commonly through protection as the corresponding acetonide).  
______________________________________________________________________ 
 
Figure 1-2. Possible chemical manipulations of c-DHC 3c[40r]  
______________________________________________________________________ 
 
Through the sorts of manipulations described above, and as shown in Figure 1-3, the 
natural products and natural product-like systems 17-34[40l,40q,57,65,71-75] have been 
produced from cis-1,2-dihydrocatechols such as 3c. These include the enantiomerically 
related modifications of the steroid-like compounds 17 and 18[70] as well as the ribisins 
(or analogues thereof) 19,[43] 20,[43] 21,[43] 22[44] and 23,[44] compounds originally isolated 
by Fukuyama and co-workers[45] from natural sources and said to be potentially useful in 
promoting immune function or treating gastrointestinal cancer.  
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______________________________________________________________________ 
 
Figure 1-3. Natural products and related systems derived from cis-bromodiol 3c by the Banwell 
Group 
______________________________________________________________________ 
 
The 2008 synthesis of ent-narciclasine by Matveenko and Banwell[76] (see Scheme 1-2) 
serves to highlight the utility of some of these types of manipulations. The reaction 
sequence commenced with the diastereoselective conversion of the cis-diol in 3c into the 
corresponding p-methoxybenzylidene acetal 35. This was followed by cis-1,2-
dihydroxylation of the latter compound under the UpJohn conditions,[77] a process that 
proceeded with excellent levels of regio- and diastereo-control, to give diol 36. The 
reaction occurred at the more nucleophilic non-halogenated double bond and such that 
the hydroxyl groups were introduced onto the sterically less congested exo-face of the 
substrate. Conversion of compound 36 into its MOM-ether 37 followed by reductive 
cleavage of the PMP-acetal unit with DIBAL-H then afforded compound 38. The 
regioselectivity observed in the conversion 37 ® 38 is most likely the result of selective 
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coordination of the DIBAL-H to that acetal oxygen within the former compound remote 
from the sterically demanding bromine and so leading to the cleavage of acetal C-O bond 
remote from this halogen atom. As a result, the observed benzyl ether 38 was produced 
as the major product of reaction. Further manipulations, including O-
protection/deprotection and a microwave-promoted Overman rearrangement reaction,[78] 
then gave compound 42. Finally, Suzuki-Miyaura cross-coupling of bromide 42 with 
boronate ester 43 followed by a deprotection reaction gave ent-narciclasine (45). 
 
______________________________________________________________________ 
 
Scheme 1-2. A total synthesis of ent-narciclasine (45) from cis-bromodiol 3c[76] 
______________________________________________________________________ 
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1.4 Aims of the Research Detailed in the Body of this Thesis 
 
As part of a continuing effort in the Banwell Group to develop efficient synthetic routes 
to biologically active natural products and related systems, ent-kirkamide (ent-57), (+)-
lycorine (ent-101) and (+)-narseronine (ent-29) (see Figure 1-4) were each targeted for 
synthesis by the author. This choice of targets followed from the synthetically challenging 
nature of their structures, their (potentially) interesting biological activities and the 
likelihood of their being accessible from the homochiral c-DHCs 3c or 3d. Specifically, 
Chapter Two details approaches to the total syntheses of the newly discovered natural 
product kirkamide and its enantiomer while the next one (Three) describes approaches to 
(+)-lycorine, a key member of the Amaryllidaceae family. Chapter Four describes a total 
synthesis of (+)-narseronine, the acquisition of which constitutes an enantiodivergent 
synthesis by virtue of earlier studies carried out within the Banwell Group. The final 
chapter (Five) presents all of the experimental details and spectral data that underpin the 
outcomes of the work reported in the preceding three Chapters, while the appendices that 
follow include summaries of the author’s work (in the form of reaction schemes) and the 
X-ray data sets acquired during the course of the author’s studies.  
 
______________________________________________________________________ 
 
Figure 1-4. The target molecules associated with the work detailed in this thesis 
______________________________________________________________________ 
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2.1 Overview 
 
2.1.1 Background  
 
Symbiotic relationships between organisms are often mediated by small molecules and 
these have become a matter of interest to those concerned with identifying new lead 
compounds for pharmaceutical development.[1] There are at least three different types of 
symbiosis:[2] 
 
Ø Commensalism: One organism benefits while its partner is neither harmed nor 
benefited. 
Ø Mutualism: Both organisms benefit. A so-called facultative mutualist can survive 
without its partner whereas the corresponding obligate mutualist can’t survive on its 
own. 
Ø Parasitism: One organism, termed the parasite, benefits while the other, termed the 
host, is harmed. 
 
Generally, a stable symbiotic relationship emerges through long-term evolution and 
during this process often becomes cyclic in nature. Great advances[3] have been made in 
the area through the identification of the chemical elements involved in such relationships 
and their modes of regulatory action. One such class of compounds is the aminocyclitols. 
Iwasa and his group reported the isolation of first such natural product from a soil sample 
in the 1970s[4a] and others were identified rapidly thereafter. Some representative 
examples (46-56) are shown in Figure 2-1.[4b] Various studies established that these 
compounds display, inter alia, antifungal, insecticidal, antibacterial and a-glucosidase 
inhibitory activities.[4] Anti-arthritic effects have been attributed to the epoxyquinomicins, 
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another type of so-called C7N aminocyclitol lacking a sugar moiety.[4f] More significantly, 
in 2002 it was reported[4g] that the C7N compound cetoniacytone A (52) exerts potent 
inhibitory effects against a number of cancer lines, including hepatocellular carcinoma 
and breast adenocarcinoma. Certain synthetically or semi-synthetically-derived C7N 
compounds have also been shown to display antiproliferative activity[4h] against smooth 
muscle cells as well as anti-inflammatory,[4i] immunomodulatory[4j] and anti-HIV[4k] 
properties. As a result of their potential applications as agrochemicals and drugs, 
considerable effort has been devoted to the study of such compounds. 
 
______________________________________________________________________ 
 
Figure 2-1. Representative C7N aminocyclitol natural products 
______________________________________________________________________ 
 
2.1.2 Isolation and Biological Evaluation of Kirkamide (57)  
 
In a recent study conducted by Gademann and co-workers on bacterial leaf nodule 
symbiosis they isolated, by chromatographic methods, a new C7N aminocyclitol named 
kirkamide.[5] On the basis of genomic evidence,[6] this natural product was considered to 
be biosynthesized by Candidatus Burkholderia kirkii (B. kirkii), the obligate leaf 
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symbiont of Psychotria kirkii (P. kirkii). The structure of kirkamide was initially proposed 
on the basis of high resolution ESI-MS as well as 1H-NMR, 13C-NMR, 1H-1H COSY and 
1H-13C HMBC spectroscopic analyses. However, the final confirmation of this came from 
a single crystal X-ray analysis[5,7] that established kirkamide was represented by structure 
57, as shown in Figure 2-2. Studies of its biological activities[8] then followed and these 
suggested that the likely reason for the production of this bacterial metabolite is the 
protection of the associated plant from being eaten by various arthropods, especially 
certain insects. In other words, kirkamide is an antifeedant compound that protects the 
host plant.[9] 
 
______________________________________________________________________    
                                                                                         
 
 
  
 
 
Figure 2-2. Leaf nodules and the structure assigned to kirkamide (57)  
______________________________________________________________________ 
 
2.1.3 Previous Syntheses of Kirkamide (57) 
 
In order to obtain sufficient quantities of kirkamide for biological studies, Gademann[5] 
reported its synthesis from methyl-N-acetyl-D-glucosamine 58[10] by the route shown in 
Scheme 2-1. Thus, subjecting the latter compound to a Garegg-Samuelsson reaction 
using PPh3, imidazole and molecular iodine produced the anticipated iodide 59[11] that 
was treated with acetic anhydride in pyridine then AgF to give the required enol ether 60 
(50% yield over three steps).[12] Solvolysis of the last compound with ammonia-
containing methanol followed by benzylation of the product trans-diol then provided the 
key intermediate 61 (36% overall yield from compound 60)[12] that was, in turn, subjected 
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OHOH
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to a Ferrier carbocyclisation reaction using HgSO4 and H2SO4[13,14] to form 
cyclohexanone 62 as a 96:4 mixture of diastereoisomers. Silyl protection followed by 
triflation with Comins’ reagent[15,16] allowed for the smooth conversion of ketone 62 into 
derivative 63 (39% from 61). Stille cross-coupling[17a-d] of the latter compound with (tri-
n-butylstannane)-methanol in the presence of Pd(PPh3)4 and LiCl under microwave 
irradiation then gave the pivotal 1º-alcohol 64 (85%). A series of deprotection steps 
followed[18] that involved an initial treatment with TBAF and then a Birch reduction (so 
as to remove the benzyl ether residues) and so affording the target natural product 57 in 
59% yield over these steps. The spectral data derived from the synthetic kirkamide 
matched those obtained on the natural product.  
 
______________________________________________________________________ 
 
Scheme 2-1. Reaction conditions: (a) PPh3, imid., I2, THF, reflux, 0.25 h; (b) Ac2O, py., rt, 24 h; 
(c) AgF, py., rt, 48 h, exclusion of light, 50% over three steps; (d) NH3, MeOH, rt, 3 h; (e) NaH, 
BnBr, DMF, 0 °C, 12 h, 36% over two steps; (f) HgSO4, 1,4-dioxane/aq. H2SO4 (5 mM) (2:1 v/v), 
microwave irradiation, 60 °C, 0.25 h; (g) TBSOTf, 2,6-lutidine, THF, 0 °C, 12 h, 63% over two 
steps; (h) Comins’ reagent, NaHMDS, THF, −78 °C, 0.08 h, 62%; (i) n-Bu3SnCH2OH, Pd(PPh3)4, 
LiCl, 1,4-dioxane, microwave irradiation, 105 °C, 1 h, 85%; (j) TBAF, THF, rt, 3 h, 98%; (k) 
Na/NH3, THF, −78 °C, 0.5 h, 59%.  
______________________________________________________________________ 
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2.2 Initial Attempts to Synthesize Kirkamide (57) from cis-1,2-Dihydrocatechol 3c 
 
2.2.1 Retrosynthetic Analysis 
 
Given the structural resemblance of kirkamide (57) to the homochiral cis-1,2-
dihydrocatechol 3c the first objective of the author’s research was to establish if the latter 
compound could be converted to the former. A synthetic strategy that might allow for this 
is shown, in retrosynthetic form, in Scheme 2-2. 
 
______________________________________________________________________ 
 
Scheme 2-2. Retrosynthetic analysis of kirkamide (57) leading to the identification of metabolite 
3c as a possible starting material 
______________________________________________________________________ 
 
It was thus envisaged that the target molecule 57 could be obtained, in the closing stages 
of the proposed synthesis, by hydrolysis of the cyclic carbamate 65 and N-acylation of 
the resulting aminocyclitol. Compound 65 could itself be derived through the application 
of, (i), a Mitsunobu reaction to establish the correct stereochemistry at C4 and, (ii), Stille 
cross-coupling chemistry of the same type as employed by Gademann for attaching the 
hydroxymethyl group to compound 66. The key intermediate 66 was expected to be 
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available through a cyclisation reaction involving N-benzoylcarbamate 67, access to 
which would exploit the methodology developed by Pinkerton[19] who showed that diol 
68 could be readily obtained from the homochiral metabolite 3c. 
 
2.2.2 Attempts to Implement the Proposed Synthetic Plan 
 
Attempts to implement the synthetic approach defined above involved the initial 
conversion 3c ® 67 as shown in Scheme 2-3. Thus, upon treatment of cis-1,2-
dihydrocatechol 3c with NBS in wet THF bromohydrin 69 was obtained in 83% yield and 
this was then converted into the desired epoxide 68 (86%) on treatment with sodium 
methoxide.[19] Subjecting the later compound to benzoyl isocyanate (72),[20] prepared by 
treating benzamide (70) and oxalyl chloride (71) in refluxing 1,2-dichloroethane, gave 
the anticipated product 67[21] (80%) in a regioselective manner. The moisture sensitive 
nature of benzoyl isocyanate necessitated that this last reaction was performed under 
strictly anhydrous conditions.  
______________________________________________________________________ 
 
Scheme 2-3. Reaction conditions: (a) NBS, THF/H2O (4:1 v/v), 22 °C, 4 h, 83%; (b) NaOMe, 
THF, 0 to 22 °C, 3 h, 86%; (c) 1,2-dichloroethane, 85 °C, 5 h, 98%; (d) THF, −78 to 22 °C, 2 h, 
80%. 
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The next step of the reaction sequence (see Scheme 2-4) required the engagement of acyl 
carbamate 67 in a 5-(enolexo)-exo-tet cyclisation reaction so as to form (after benzoyl 
group loss) either the cyclic carbonate 66 or 73 depending on whether the process 
proceeded in an SN1 or SN2 fashion. However, despite exploring the use of a range of 
bases including K2CO3, NaH, KH and KHMDS, neither of these products was observed. 
When the readily derived TBS-ether 74 (81%) of compound 67 was subjected to the same 
range of conditions neither of the anticipated products 75 or 76 was observed. The failure 
to effect the cyclisation of either of compounds 67 or 74 is undoubtedly a consequence 
of stereoelectronic effects, most particularly the associated conjugate base being unable 
to adopt the correct trajectory required to engage in an SN2 reaction with the adjacent 
electrophilic center. In light of these results a revised approach was pursued that would 
lead to ent-kirkamide first. Details are provided in the following section. 
 
______________________________________________________________________ 
 
Scheme 2-4. Reaction conditions: (a) i) K2CO3, TBAC, THF, 22 °C or ii) NaH, THF, 0 to 22 °C 
or KH, THF, 0 to 22 °C or KHMDS, THF, –78 to 22 °C; (b) TBS-Cl, TEA, DCM, 22 °C, 12 h, 
81%. 
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2.3 Approaches to ent-Kirkamide (ent-57) 
 
2.3.1 Retrosynthetic Analysis 
Informed by the outcomes detailed above, a revised approach to the target compound, or 
at least the enantiomer thereof (viz. ent-kirkamide) in the first instance, was developed. 
The relevant retrosynthetic analysis is shown in Scheme 2-5.  
______________________________________________________________________ 
 
Scheme 2-5. Retrosynthetic analysis of ent-kirkamide (ent-57) leading to the identification of 
metabolite 3c as possible starting material 
______________________________________________________________________ 
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accessible by subjecting compound 68 to a two-fold Mitsunobu reaction.[22] Epoxide 68 
is a known compound that is readily obtained by established and simple methods[19] from 
the homochiral metabolite 3c. 
 
2.3.2 Opening Stages of the Approach to ent-Kirkamie (ent-57) 
The pursuit of a total synthesis of compound ent-57 by the route defined above started 
with the conversion (see Scheme 2-6) of enantiomerically pure diol 3c, via an established 
two-step process,[19] into epoxide 68 (86%). Subjecting the latter compound to the 
foreshadowed Mitsunobu reaction using DEAD, p-nitrobenzoic acid and 
triphenylphosphine then gave the bis-ester 80 in 86% yield. Treating a methanolic 
solution of compound 80 with catalytic amounts of sodium methoxide[22b] then afforded 
the diol 79 in 90% yield. Reaction of this last compound with ca. 1.2 molar equiv. of 
freshly prepared benzoyl isocyanate then delivered, as anticipated, the desired carbamate 
78 in 85% yield. The structure of compound 78 followed from a single crystal X-ray 
analysis of a derivative (see below). 
______________________________________________________________________ 
 
Scheme 2-6. Reaction conditions: (a) NBS, THF/H2O (4:1 v/v), 22 °C, 4 h, 83%; (b) NaOMe, 
THF, 0 to 22 °C, 3 h, 86%; (c) PPh3, p-NO2PhCO2H, DEAD, THF, 0 to 22 °C, 4 h, 86%; (d) 
NaOMe, MeOH, 0 °C, 0.1 h, 90%; (e) benzoyl isocyanate, THF, −78 to 22 °C, N2, 2 h, 85%. 
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As shown in Scheme 2-7, when compound 78 was treated with a mixture of potassium 
carbonate and tetra-n-butylammonium chloride a cyclisation reaction now took place to 
give a chromatographically separable mixture of the cyclic carbamates 81 (32%) and 82 
(31%). Each of these was subjected to extensive spectral analyses, including those 
involving 1H-NMR, 13C-NMR, IR, LR/HRMS techniques.  
______________________________________________________________________ 
 
Scheme 2-7. Reaction conditions: (a) K2CO3, TBAC, THF, 22 °C, 4 h, 81 in 32% yield and 82 in 
31% yield; (b) BzCl, TEA, DMAP, THF, 22 °C, 6 h, 83%.  
______________________________________________________________________ 
 
The final confirmation of the illustrated structures of these compounds followed from 
single-crystal X-ray analyses on each (see Figures 2-3 and 2-4 for the derived ORTEPs 
of compounds 81 and 82, respectively). Since there were also some indications of the co-
production of the highly polar and intractable diol 83 in this cyclisation reaction, for the 
purposes of progressing the synthesis exhaustive O-benzoylation of the crude reaction 
mixture was undertaken (using BzCl, TEA and DMAP) and by such means compound 82 
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81, 82 and 83 arose through trans-O-benzoylation reactions involving the primary 
product of this reaction, namely the N-benzoyl derivate of 81. 
 
______________________________________________________________________ 
 
Figure 2-3. ORTEP derived from the single-crystal X-ray analysis of compound 81 with labelling 
of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
Figure 2-4. ORTEP derived from the single-crystal X-ray analysis of compound 82 with labelling 
of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. 
______________________________________________________________________ 
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2.3.3 Attempts to Complete a Synthesis of ent-Kirkamide (ent-57) 
 
Compounds 81 and 82 embody key structural elements of the target compound (ent-57) 
but, most notably, lack the hydroxymethyl group. Various attempts to introduce this 
group through manipulation of the alkenyl bromide moiety within compounds 81 and 82 
are shown in Scheme 2-9. Each was subjected to various Stille cross-coupling 
conditions[17] using (tri-n-butylstannane)methanol or a derivative[23] as the nucleophile. 
Unfortunately, all of these failed. These adverse outcomes could be attributed to the lack 
of reactivity of the alkenyl bromide residue within each of these substrates. Accordingly, 
an investigation of the analogous behavior of the corresponding and likely more reactive 
alkenyl iodides was pursued. Details are presented immediately below.  
______________________________________________________________________ 
 
Scheme 2-9. Reaction conditions: (a) n-Bu3SnCH2OH or n-Bu3SnCH2OTBS, Pd(PPh3)4, LiCl, 
1,4-dioxane, reflux or microwave irradiation; (b) n-Bu3SnCH2OH or n-Bu3SnCH2OTBS, CsF, 
Pd(PPh3)4, CuI, DMF, 22 °C. 
______________________________________________________________________ 
 
In order to obtained the required iodides, and as shown in Scheme 2-10, metabolite 3d 
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subjecting this to reaction with a mixture of p-nitrobenzoic acid, triphenylphosphine and 
DEAD afforded the bis-ester 90 in 88% yield. Treatment of compound 90 with ammonia-
saturated methanol resulted in ester cleavage and the formation of the required diol 91 
(93%). 
______________________________________________________________________ 
 
Scheme 2-10. Reaction conditions: (a) NBS, THF/H2O (4:1 v/v), 0 to 22 °C, 1 h, 93%; (b) NaH, 
THF, 0 to 22 °C, 5 h, 92%; (c) PPh3, p-NO2PhCO2H, DEAD, THF, 0 °C, 4 h, 88%; (d) MeOH 
(NH3 sat.), 22 °C, 1 h, 93%. 
______________________________________________________________________ 
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acylated aminotriol 99 which could be engaged in a palladium-catalysed 
carbomethoxylation reaction[24] and thus affording the unsaturated ester 100 in 78% yield.  
 
______________________________________________________________________ 
 
Scheme 2-11. Reaction conditions: (a) i) benzoyl isocyanate, THF, −78 to 0 °C, N2, 1 h; ii) K2CO3, 
TBAC, THF, 22 °C, 2 h; iii) BzCl, TEA, DMAP, THF, 0 to 22 °C, 18 h, 40% from 91; (b) n-
Bu3SnCH2OH, Pd(PPh3)4, LiCl, 1,4-dioxane, reflux or n-Bu3SnCH2OH, Pd(PPh3)4, CsF, CuI, 
DMF, 22 °C; (c) i) benzoyl isocyanate, THF, −78 to 0 °C, N2, 1 h; ii) K2CO3, TBAC, THF/H2O 
(10:1 v/v), 22 °C, 2 h; iii) NaOH, MeOH/H2O (1:1 v/v), reflux, 2 h; iv) Ac2O, MeOH/H2O (1:1 
v/v), 22 °C, 2 h, 82% from 91; (d) CO (1 atm), Pd(OAc)2, PPh3, TEA, 40 °C, 6 h, 78%. 
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The 1H-NMR spectrum of ester 100 (see Figure 2-5) was completely consistent with the 
assigned structure. For instance, the most obvious two signals observed at δ 2.00 and 3.78 
ppm are assigned to the methyl groups associated with the amide and ester moieties, 
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couplings (dd, J = 4.7 and 1.3 Hz) arising from three- and four-bond interactions with the 
allylic oxymethine protons. The 13C-NMR spectrum (see Figure 2-6) exhibits ten distinct 
carbon resonances with those appearing at δ 173.7 and 168.3 ppm being assigned to the 
corresponding ester and amide carbonyls and the resonances due to alkenyl carbons 
appearing at δ 138.2 and 135.2 ppm. 
 
______________________________________________________________________ 
 
 
Figure 2-5. 1H-NMR spectrum of compound 100 (recorded in CD3OD at 400 MHz) 
______________________________________________________________________ 
 
Although a wide-range of reagents, including DIBAl-H, LAH, NaBH4 and LiBH4 were 
examined, the reduction of ester 100 to the desired hydroxymethylated target molecule 
ent-57 could not be accomplished. However, continuing efforts to complete the total 
synthesis of ent-kirkamide (ent-57) are now underway in the author’s laboratories. 
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______________________________________________________________________ 
  
 
Figure 2-6. 13C-NMR spectrum of compound 100 (recorded in CD3OD at 100 MHz) 
______________________________________________________________________ 
 
2.4 Conclusion 
Various selective chemical manipulations of the cis-1,2-dihydrocatechols 3c and 3d have 
led to the concise assembly of the framework (incorporating almost all of the required 
functionalities in appropriate configurations) associated with ent-kirkamide (ent-57), the 
enantiomer of the insect antifeedant natural product kirkamide (57). As such, the stage 
has now been set for the completion of the first total synthesis of ent-kirkamide. The key 
remaining step is the manipulation of the halogenated center within compounds such as 
compound 99 so as to introduce pivotal hydroxymethyl group. This may be best effected 
through reduction of an ester precursor (such as compound 100). Given that the 
enantiomeric form of metabolite 3d is also available, a successful synthesis of ent-
kirkamide by the means just defined would automatically “translate” into a synthesis of 
the natural product itself. Furthermore, there are likely to be good prospects for exploiting 
the above-mentioned methodology in the generation, in either enantiomeric form, of a 
raft of analogues of this fascinating natural product. 
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3.1 Overview 
 
3.1.1 The Biological Significance of Amaryllidaceae Alkaloids 
 
For millennia, medicinal herbs have served as a globally accessible treatment for a variety 
of diseases.[1] Herbs from the Amaryllidaceae family are widely distributed in tropical 
and subtropical regions and have been found to display interesting biological activities 
(as well as being decorative plants). Their use as medicines can be traced back to the 
fourth century B.C. when Hippocrates of Cos applied an oil extracted from the daffodil 
Narcissus poeticus to treat uterine tumors.[1] In the first century A.D. Pliny the elder 
described the use of extracts of various members of the Amaryllidaceae family in the 
topical treatment of cancer.[1] Furthermore, the bulbs of Lycoris radiate have long served 
in traditional Chinese medicine[2] as sources of treatments for furuncles, carbuncles, 
laryngeal complications and suppurative wounds. In a more contemporary setting, the 
Amaryllidaceae alkaloid glanthamine represents a now widely approved pharmaceutical 
for the treatment of mild to moderate forms of Alzheimer’s disease.[3]  
 
In view of their fascinating history and biological properties, increasing efforts have been 
devoted to exploring the biosynthesis[4] of the Amaryllidaceae alkaloids as well as 
elucidating their biological activities that include, as established thus far, analgesic,[5a] 
antiviral,[5b] antineoplastic,[5c-e] and insect antifeedant properties.[5f,5g] A flow-on effect of 
such work has been the investigation of synthetic approaches[6] to these systems. These 
investigations, which have been extensive, are often prompted by the need to secure 
adequate quantities of material or to provide analogues that might exhibit superior 
efficacy and/or metabolic stability. 
 
Chapter Three 
_________________________________________________________________________________________________________________________________________________________________________ 
 45 
3.1.2 Isolation and Characterization of (–)-Lycorine (101)  
 
The alkaloid (−)-lycorine (101) is an important member of Amaryllidaceae alkaloid 
family and occurs in a range of flowering plants including the bush lily, surprise lily and 
daffodils[7] (see Figure 3-1). It was first isolated in the late 19th century[8] and given that 
it makes up 1% of the dry weight of the relevant daffodil bulbs it is considered to be the 
most abundant of the nitrogen bases in this family. Determined efforts to establish its 
structure was started in the mid-1930s by various Japanese groups and this task was 
eventually completed some decades later through a single-crystal X-ray analysis of the 
hydrobromide salt of the dihydrolycorine derivative 102.[9]  
______________________________________________________________________ 
                                                                  
   
 
                                                                             
 
 
     
Figure 3-1. Amaryllidaceae herbs (from left to right): the bush lily, surprise lily and daffodil & 
the associated alkaloid (−)-lycorine (101) and its derivative 102 
______________________________________________________________________ 
(−)-Lycorine (101) is a toxic and crystalline compound that has been employed as a potent 
emetic. It has also been shown to act as a strong inhibitor of growth and cell division in 
higher plants, algae and yeast[10] while also slowing protein and DNA syntheses in murine 
cells and such that it affects the in vivo growth of murine-transplantable ascites tumors.[10] 
It also displays potent inhibitory effects against severe acute respiratory syndrome 
coronavirus (SARS-CoV),[11] the human enterovirus 71 (EV71)[12] and H5N1 [by 
blocking vRNP (viral ribonucleo-protein) nuclear export in cells].[13] (−)-Lycorine 
displays high antiretroviral activities (against, for example, HIV-1).[14] 
Immunosuppressive properties have also been attributed to (−)-lycorine.[11]  
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3.1.3 Previous Syntheses of Lycorine 
 
Because of its significant biological activities and intriguing tetracyclic structure, 
substantial efforts have directed towards the synthesis[15] of lycorine and related alkaloids 
although most of these led to the racemic form of the relevant target compound.[16] In 
1975 Murata[16a] reported the first the total synthesis of (±)-lycorine and subsequent 
efforts[16b-16f] in this area were mainly focused on varying the orders in which the 
associated A-, B-, C- and D-rings were introduced. These various syntheses of racemic 
materials have been nicely summarized in a 2015 review by Liu.[16f] As the focus of the 
author’s research was on developing a synthesis of the enantiomer of the natural product, 
viz. (+)-lycorine (ent-101), a summary of the limited amount of earlier work[17] 
undertaken on this matter is presented immediately below.  
 
3.1.3.1   The Asymmetric Synthesis of (+)-Lycorine (ent-101)  
 
In 1996 Schultz and co-workers[17a] reported the first syntheses of (+)-lycorine (ent-101) 
and (+)-1-deoxylycorine (103) (see Figure 3-2) in 15 and 13 steps, respectively. Details 
are given in Scheme 3-1. Thus, Birch reduction-alkylation of chiral benzamide 104 with 
2-bromoethyl acetate followed by saponification gave compound 105 in 96% yield as a 
single diastereoisomer.[18] Alcohol 105 was itself converted into azide 106 that was 
subjected to acid-catalyzed enol ether hydrolysis to afford amide 107. Iodolactonization 
of ketone 107 provided lactone 108, treatment of which with triphenylphosphine resulted 
in an aza-Wittig reaction took place to give the enantiomerically pure imine 109 (50% 
overall yield from 105). Acylation of compound 109 with either 2-bromo- and 2-
iodopiperonyloyl chloride generated the corresponding enamides 110a (98%) and 110b 
(99%), respectively. Epoxides 111a (73%) and 111b (92%) were then obtained by 
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treating either of iodolactones 110a and 110b with the in situ generated lithium salt of 
benzyl alcohol. Upon treatment of these so-formed oxiranes with tri-n-butyltin hydride in 
the presence of AIBN they were each engaged in 6-endo-trig reductive free-radical 
cyclisation reactions to form the lactam 112 (in 53% and 51% yields, respectively). 
 
______________________________________________________________________ 
 
Figure 3-2. (+)-lycorine (ent-101) and its congener (+)-1-deoxylycorine 103 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
Scheme 3-1. Reaction conditions: (a) i) K/NH3, t-BuOH (1.0 mol equiv.), −78 °C, 0.25 h; ii) 
BrCH2CH2OAc (2.0 mol equiv.), −78 to 25 °C, 0.5 h; iii) KOH, MeOH, 25 °C, 6 h, 96%; (b) 
DEAD, PPh3, (PhO)2P(O)N3, THF, 0 to 25 °C, 15 h, 73%; (c) aq. HCl, MeOH, 25 °C, 15 h, 95%; 
(d) I2, THF/H2O (1:1 v/v), 25 °C, 12 h, 82%; (e) PPh3, THF, reflux, 9 h, 90%; (f) ArCOCl (1.0 
mol equiv.), TEA, DCM, 0 to 25 °C, 12 h, 98% to 99%; (g) BnOH, THF, n-BuLi, −78 to 25 °C, 
5 h, 73% to 92%; (h) AIBN, n-Bu3SnH, benzene, reflux, 16 h, 53%. 
______________________________________________________________________ 
 
OHN
OH
O
O
ent-101                                                  103
N
OH
O
O
OMe
N
O OMe
N
O OMe
X
OMe
105, X = OH
106, X = N3b
a
104                                                                                            107                                        108
c N
O OMe
N3
d
O
O
I O
N3
e
O
I O
N
f
O
I O
N
O
O O
X
109110a, X = Br
110b, X = I
110c, X = H
g
O CO2Bn
N
O
O O
X
111a, X = Br
111b, X = I
111c, X = H
h
O CO2Bn
N
O
O
O
112
O
Chapter Three 
_________________________________________________________________________________________________________________________________________________________________________ 
 48 
The elaboration of lactam 112 to target ent-101 proved more difficult than initially 
expected. The ultimately effective route is shown in Schemes 3-2. So, under standard 
conditions,[19] compound 112 was converted into hydroxyselenide 113 and oxidation of 
the latter compound with sodium metaperiodate followed by thermolysis of the resulting 
selenoxides gave allylic alcohol 114 in 81% yield over these two steps. Upon treatment 
of compound 114 with a mixture of acetic acid/acetic anhydride in the presence of sulfuric 
acid at 50 °C an allylic rearrangement took place[20] to give a mixture of solvolysis 
products that included the desired, chromatographically separable and crystalline allylic 
acetate 115. This was obtained in 34% yield.  
 
______________________________________________________________________ 
 
Scheme 3-2. Reaction conditions: (a) NaBH4, EtOH, PhSeSePh, 22 °C, 1h, 93%; (b) NaIO4, H2O, 
THF, 22 °C, 12 h, 87%; (c) AcOH, Ac2O, H2SO4, 50 °C, 0.25 h, 34%; (d) dimethyldioxirane, 
acetone, 0 °C, 96 h, 46%; (e) 10% Pd/C, EtOH, H2 (1 atm), 1 h, 90%; (f) hv, Pyrex, acridine, 
benzene, t-BuSH, 1.75 h, 50%; (g) Ac2O, DMAP, 22 °C, 3 h; (h) LiAlH4, THF, reflux (no yield 
specified over steps h and i); (i) LiAlH4, THF, reflux, 4 h, 70%. 
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Upon treatment of compound 115 with dimethyldioxirane in acetone epoxy-ester 116 was 
obtained (46%) and this was, in turn, converted into the corresponding carboxylic acid 
117 (90%) through hydrogenolytic cleavage of the benzyl ester. Okada’s method for 
photochemical decarboxylation[21] was then applied and allowed for the conversion of 
compound 117, via a radical process, into trans-diol mono-acetate 118 (50%). 
Acetylation of compound 118 under standard conditions then afforded the desired di-
acetate 119 (no yield specified), the spectral data for which were in good agreement with 
those reported for the corresponding (previously prepared) racemate.[22] Reduction of 
compound 119 with LAH then gave (+)-lycorine (ent-101), the 1H-NMR spectrum of 
which was identical to that of an authentic sample provided by Professor George Pettit.[17a] 
Moreover, the spectral data obtained on the corresponding diacetates were identical, in 
all respects, with each other. By such means, the first asymmetric total synthesis of 
enantiomerically pure (+)-lycorine (ent-101) was achieved in 15 steps.  
 
3.1.3.2   The Asymmetric Synthesis of (–)-Lycorine (101)  
 
In 2009, Tomioka and co-workers[17b] described the first asymmetric total synthesis of 
(−)-lycorine (101) (see Scheme 3-3). The key steps involved a double Michael addition 
reaction, a subsequent Curtius rearrangement and then a Bischler-Napieralski reaction. 
An asymmetric conjugate addition[23] of an in situ generated aryllithium 120 with the 
symmetric Michael acceptor 121 containing two enoate moieties was mediated by the 
chiral (and recyclable) ligand 122. This reaction was conducted in the presence of 
chlorotrimethylsilane that accelerated the production of, via the enantiomerically pure 
enolate 123, a 9:1 mixture of the all-trans cyclohexane 124 (92% e.e.) and a trans-cis 
isomer in a combined yield of 97%.[24] This mixture of compound 124 and its isomer was 
then treated with aq. HCl in refluxing ethanol so as to remove both the associated tert-
Chapter Three 
_________________________________________________________________________________________________________________________________________________________________________ 
 50 
butyl and trimethylsilyl groups. This was followed by esterification of the less hindered 
carboxylic acid moiety and reketalization to give mono-carboxylic acid 125 in 77% yield. 
Upon treatment of this compound with DPPA and TEA[25] in refluxing tert-butanol an 
acyl azide was formed that underwent an in situ Curtius rearrangement to generate 
carbamate 126 (80%) as a single enantiomer (> 99% e.e.). A reductive alkylation 
sequence then followed and treatment of the ring-fused pyrrolidine so-formed with ethyl 
chloroformate afforded the carbamate 127 in 56% yield. This compound was, in turn, 
subjected to a Bischler-Napieralski cyclisation reaction thus giving the key tetracyclic 
compound 128 in 95% yield.  
 
______________________________________________________________________ 
 
Scheme 3-3. Reaction conditions: (a) TMSCl, toluene, −78 °C, 1.5 h, 87%; (b) i) aq. HCl, EtOH, 
reflux, 1 h; ii) (CH2OH)2, TsOH, reflux, 2 h, 77% over two steps; (c) DPPA, TEA, t-BuOH, reflux, 
96 h, 80%; (d) i) TFA, PhSMe, rt, 1 h; ii) NaOMe, MeOH, rt, 48 h; iii) LiAlH4, THF, reflux, 3 h; 
iv) ClCO2Et, TEA, DCM, rt, 8 h, 56% over four steps; (e) POCl3, 90 °C, 8 h, 95%. 
______________________________________________________________________ 
TMS
LiO
O
+
t-BuO2C
OO
CO2t-Bu
Ph
MeO OMe
Ph
O
O
TMS
O
O CO2t-Bu
CO2t-Bu
Ot-Bu
CO2t-Bu
O
O H
Ar
H
H
O-Lia
120                                   121                               122                                                     123
O
O
O
O CO2Et
CO2H
O
O
O
O
N
CO2Et
O
O
N
O
O
bc
d
 127                                                                128
e
O
O
O
O CO2Et
NHBoc
  126                                                                125                                                            124
Chapter Three 
_________________________________________________________________________________________________________________________________________________________________________ 
 51 
The reaction sequence used to convert compound 128 into the di-O-acetyl derivative, 135, 
of (–)-lycorine is shown in Scheme 3-4. Thus, upon treatment with TIPSOTf in the 
presence of TEA, ketone 128 was transformed into the corresponding TIPS-enol ether 
129 (80%). Oxidation of the latter compound with m-CPBA under Magnus’ conditions[26] 
gave the desired m-chlorobenzoate 130 that was subjected to a regioselective 
dehydrogenation reaction.[27] These involved phenylselenylation of the corresponding 
TMS enol ether, oxidation of the so-obtained selenide with sodium metaperiodate and 
thermolysis of the selenoxides. By such means the desired enone 131 was obtained in 52% 
yield.  
______________________________________________________________________ 
 
Scheme 3-4. Reaction conditions: (a) TIPSOTf, TEA, DCM, 0 °C to rt, 24 h, 58%; (b) i) m-CPBA, 
imid., DCM, 0 °C to rt, 1 h; ii) aq. HF, acetonitrile, rt, 12 h, 64% over two steps; (c) i) TMSOTf, 
TFA, DCM, 0 °C to rt, 2 h; ii) PhSeCl, DCM, 0 °C, 1 h; iii) NaIO4, THF/H2O (1:1 v/v), 0 °C to 
rt, 12 h, 52% over three steps; (d) NaBH4, CeCl3•7H2O, 0 °C, 0.17 h, 90%; (e) LiAlH4, THF, 
reflux, 4 h; (f) Ac2O, DMAP, DMSO/DCM (1:1 v/v), rt, 12 h, 47% over steps e and f; (g) i) p-
NO2PhCO2H, DEAD, PPh3, benzene, rt, 3 h, 84%; ii) LiAlH4, THF, reflux, 4 h; (f) Ac2O, DMAP, 
DMSO/DCM (1:1 v/v), rt, 12 h, 52% over steps g (ii) and f. 
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Enone 131 was subjected to a re-face-selective Luche reduction to afford the a-
configured allylic alcohol 132 (90%). Reduction of this compound with LAH provided 
the cis-diol 133 that was converted into the corresponding di-O-acetyl 134 (47% over two 
steps)[28] under standard conditions. The spectral data, specific rotation and melting point 
derived from this material matched those previously reported[28] for an authentic sample 
of this material derived from the target natural product. In order to secure the trans-diol 
motif contained in the natural product, compound 132 was subjected to a Mitsunobu 
reaction[29] using p-nitrobenzoic acid as nucleophile. Hydrolysis of the resulting 
nitrobenzoate under conventional conditions then gave the target (−)-lycorine (101) that 
was converted into the corresponding di-acetate 135 (52% yield over two steps) under 
conventional conditions. The spectral data obtained on his material were in excellent 
agreement with those previously reported.[17a] Overall, then, (−)-lycorine (101) was 
prepared over 18 steps by Tomioka and co-workers. 
 
3.2 An Approach to the Chemoenzymatic Synthesis of (+)-Lycorine (ent-101) 
 
3.2.1 Retrosynthetic Analysis	
 
An approach to (+)-lycorine (ent-101) from cis-1,2-dihydrocatechol 3c is shown in 
retrosynthetic form in Scheme 3-5. This borrows from previous work[30,31] carried out in 
the Banwell Group. So, it was thought that the target molecule (ent-101) could be derived 
from the lactam 136 through a series of reduction reactions that might be accomplished 
in a one-pot process with, for example, LAH. Lactam 136 might itself be derived from 
the corresponding lactone 137 by subjecting it to, (i), strong base (responsible for C-N 
bond formation), (ii), selective-oxidation conditions and, (iii), dehydrogenation 
conditions. Compound 137 was thought to be available through a stereocontrolled, 
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radical-based and reductive cyclisation of the N-chloro-derivative of the 1º-amine 138. 
Previous research has shown that 1º-amine 138 could be assembled via the Suzuki-
Miyaura cross-coupling reaction[32] of compounds 139 and 140. The homochiral diol 139 
had been obtained previously and in a straightforward manner from the enantiomerically 
pure cis-1,2-dihydrocatechol 3c. Details are given below. So, the focus of the research 
work detailed in the remainder of this chapter was the implementation of the 
aforementioned route to (+)-lycorine. 
______________________________________________________________________ 
 
Scheme 3-6. Retrosynthetic analysis of (+)-lycorine (ent-101) leading to the identification of 
chiron 3c as possible starting material 
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3.2.2 Opening Stages of an Approach to the Chemoenzymatic Synthesis of (+)-Lycorine 
(ent-101)	
 
Following the protocols, as shown in Scheme 3-7, established by White,[31] the 
enantiomerically pure cis-1,2-dihydrocatechol 3c was converted into the bromohydrin 69. 
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The latter compound was then transformed into the corresponding acetonide 141 (92%) 
on treatment with 2,2-DMP and p-TsOH•H2O. Treatment of compound 141 with NaH 
followed by a 3-fold excess of the acetonitrile anion (prepared by reacting acetonitrile 
with n-butyl lithium) afforded, via an epoxide intermediate, the γ-hydroxynitrile 142 in 
88% yield and as a single diastereoisomer. Barton-McCombie deoxygenation of 
compound 142 was accomplished via the corresponding and readily prepared methyl 
xanthate 143 (90%) to afford the nitrile 139 in 87% yield. 
______________________________________________________________________ 
 
Scheme 3-7. Reaction conditions established by White:[30] (a) NBS, THF/H2O (4:1 v/v), 0 to 
22 °C, 4 h; (b) 2,2-DMP, p-TsOH•H2O, 22 °C, 2 h, 92% over two steps; (c) i) NaH, THF, 0 °C, 
0.5 h; ii) acetonitrile, n-BuLi, THF, −78 °C, 0.25 h, 88%; (d) NaH, CS2, MeI, THF, 0 to 22 °C, 
1.5 h, 90%; (e) AIBN, n-Bu3SnH, benzene, reflux, 2 h, 87%. 
______________________________________________________________________ 
 
The Suzuki-Miyaura cross-coupling reaction to be used to further the synthesis, as shown 
in Scheme 3-8, required “joining” the bromoalkene 139 with arylboronate ester 140. This 
second coupling partner was readily obtained on a multi-gram scale from piperonal (144) 
through its treatment with molecular bromine and iron powder in glacial acetic acid to 
afford bromide 145.[32a] This last compound was subjected to Pinnick oxidation 
conditions and the resulting acid converted to its methyl ester using methanol in the 
presence of concentrated sulfuric acid. By such means the previously reported[32b] ester 
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146 was obtained as a crystalline compound in 92% yield. On reaction of compound 146 
with bis(neopentylglycolato)diboron in the presence of PdCl2(dppf)•CH2Cl2 and TEA the 
arylboronate ester 140 was obtained[32c] in 91% yield. All the spectral data acquired on 
this last compound matched those reported[32] previously. With compound 140 in hand 
its Suzuki-Miyaura cross-coupling with cycloalkenyl bromide 139 was examined. On 
subjecting the reaction partners to the conditions shown in Scheme 3-8 the desired 
product 147 was obtained in 86% yield. Once again, all the spectral data obtained on this 
material were in complete accord with the assigned structure and matched those reported 
previously by Jones and co-workers.[32c] 
______________________________________________________________________ 
 
Scheme 3-8. Reaction conditions: (a) Br2, iron powder, AcOH, 0 to 22 °C, 72 h, 91%; (b) i) 
NaClO2, NaH2PO4H2O, acetone/H2O (1:1 v/v), 22 °C, 2 h, quantitative; ii) MeOH, H2SO4, reflux, 
24 h, 92%; (c) KOAc, bis(neopentylglycolato)diboron, PdCl2(dppf)•CH2Cl2, acetonitrile, reflux, 
3 h, 91%; (d) TEA, PdCl2(dppf)•CH2Cl2, THF/H2O (9:1 v/v), reflux, 2 h, 86%. 
______________________________________________________________________ 
The pathway employed in elaborating coupling product 147 into the pivotal 1°-amine 138 
is shown in Scheme 3-9. This involved treatment of the 147 with aqueous glacial acetic 
acid to provide, via an acetonide hydrolysis/lactonization process, compound 148 in 89% 
yield. Reaction of lactone 148 with TBDPS-Cl and imidazole then gave the anticipated 
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TBDPS-ether 149 (90%)[31] that was converted, in a completely chemoselective manner, 
into the corresponding 1º-amine 138 (92%) on treatment with molecular hydrogen in the 
presence of an excess of freshly prepared Raney-cobalt.[33] 
______________________________________________________________________ 
 
Scheme 3-9. Reaction conditions: (a) AcOH/H2O (4:1 v/v), 50 °C, 18 h, 89%; (b) TBDPS-Cl, 
imid., DCM, 22 °C, 12 h, 90%; (c) Raney-cobalt, H2 (1 atm), MeOH (NH3 sat.), 22 °C, 18 h, 92%. 
______________________________________________________________________ 
 
3.2.3 Formation of the Pyrrolidine D-ring of (+)-Lycorine via a Free-radical Cyclisation 
Reaction	
 
The next stage of the current approach to (+)-lycorine (ent-101) required preparing 
perhydroindole 137 from amine 138. This proved to be a non-trivial matter but after 
considerable experimentation a reliable, free-radical cyclisation process was identified. 
This is shown in Scheme 3-10 and involved adding NCS to a 0.01 M solution of 1°-amine 
138 in benzene at room temperature. The N-chloroamine so-formed was immediately 
treated with AIBN (0.05 to 0.08 mole equiv.) and while the resulting solution was being 
heated under reflux, it was also treated, over 1 h, with a benzene solution of tri-n-butyltin 
hydride. As a result, and after work-up, a chromatographically separable mixture of 
compounds 150 and 151 was obtained. The relative amounts of these products varied 
somewhat depending upon the quantities of AIBN employed and the concentration of the 
reaction mixture.  
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______________________________________________________________________ 
 
Scheme 3-10. Reaction conditions: (a) i) NCS, benzene (0.01 M), 22 °C, 0.5 h; ii) AIBN (0.05 to 
0.08 mol equiv.), n-Bu3SnH (1.2 mol equiv.), benzene, 80 °C, 4 h, in 65% to 85% combined yield 
over two steps; (b) TBAF, THF, 22 °C, 12 h, 93%. 
______________________________________________________________________ 
 
Eventually, it was established that the optimum conditions for the formation of product 
151 required a smaller portion of AIBN and a more dilute reaction mixture. So, NCS was 
added to a 0.004 M solution of 1°-amine 138 in benzene at room temperature (22 °C) to 
generate the intermediate N-chloroamine. AIBN was then added (0.04 mole equiv. in two 
portions), followed by addition, over 2 h, of a benzene solution of tri-n-butyltin hydride 
to the refluxing reaction mixture. Under these conditions, compound 151 was obtained in 
65% yield. Given the amorphous nature of this product it was subjected to treatment with 
TBAF and the corresponding and crystalline 2°-alcohol 137 (93%) was obtained. This 
material was more suitable for extensive spectroscopic analyses, including single-crystal 
X-ray analysis. The derived ORTEP is shown in Figure 3-3 and this served to confirm 
the illustrated structure and, in particular, the successful construction of the pyrrolidine 
D-ring associated with the final target. 
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______________________________________________________________________ 
 
Figure 3-3. ORTEP plot derived from the single-crystal X-ray analysis of compound 137 with 
labelling of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. 
Hydrogen atoms are drawn as circles with small radii. 
______________________________________________________________________ 
 
A possible pathway, involving free-radical intermediates, associated with the conversion 
138 ® 151 is shown in Scheme 4-6.[34] So, the initial step might involve the formation 
of the N-chloro-derivative of the compound 138 (through halogen atom transfer from 
NCS) and this derivative, viz. intermediate 152, then reacts with the tri-n-butyltin free 
radical to give the corresponding N-centered radical (and tri-n-butyltin chloride). The last 
species engages in a 5-exo-trig cyclisation reaction to yield the corresponding tetracyclic 
and relatively stable benzylic radical 153 that itself abstracts, in a stereo-selective manner, 
a hydrogen atom from tri-n-butyltin hydride to deliver product 151 (while simultaneously 
propagating the radical chain process). The exquisite facial selectivity of this hydrogen 
atom abstraction reaction is determined by the steric demands of the proximate lactone 
and TBDPS-ether units that act in concert to ensure the establishment of the illustrated R-
configuration at C15 in the product 151.  
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______________________________________________________________________ 
 
Figure 3-3. Possible mechanism for the reductive free-radical cyclisation reaction associated with 
the conversion 138 ® 151 
______________________________________________________________________ 
3.2.4 Attempts to Complete a Chemoenzymatic Total Synthesis of (+)-Lycorine (ent-
101) 
 
With the successful formation of compound 137 its elaboration to (+)-lycorine (ent-101) 
by the pathway outlined in Scheme 3-11 was pursued. Thus, treatment of lactone 137 
with sodium methoxide in methanol gave the isomeric lactam 154 in 88% yield and 
oxidation of the latter with Bobbit’s oxammonium salt[35] (generated in situ by reacting 
4-AcNH-TEMPO with p-TsOHH2O) gave the desired ketone 155 (78%) through 
selective oxidation of the less hindered hydroxyl group within precursor 154 by the 
sterically demanding oxidant. Extensive spectroscopic analyses of acyloin 155 obtained 
by this means, including single-crystal X-ray analysis (see Figure 3-4 for the derived 
ORTEP) confirmed that it possessed the illustrated structure. 
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Scheme 3-11. Reaction conditions: (a) NaOMe, MeOH, 50 °C, 4 h, 88%; (b) 4-AcNH-TEMPO, 
p-TsOHH2O, DCM, 0 to 22 °C, 3.5 h, 78%; (c) BzCl, TEA, DMAP, DCM, 0 to 22 °C, 18 h, 
73%; (d) i) TMSOTf, TFA, DCM, 0 to 22 °C, 2 h; ii) PhSeCl, DCM, 0 °C, 1 h; iii) NaIO4, 
THF/H2O (1:1 v/v), 22 °C, 15 h, 62% over three steps. 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
Figure 3-4. ORTEP plot derived from the single-crystal X-ray analysis of compound 155 with 
labelling of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. 
Hydrogen atoms are drawn as circles with small radii. 
______________________________________________________________________ 
NH O
O
O
O
OH
N OH
OH
O
O
N OH
O
O
O
O
OBzN
O
O
O
O
OBzN
O
O
O
O
OHN
OH
O
O
OHN
OH
O
O
137                                                     154                                                    155                                             136
157                                                   156
ent-101
a b
c
d
OHN
O
O
O
O
+
ent-133
O
  O1 
  O2 
  O3 
  O4 
  O5 
  N1 
  C1 
  C2 
  C3 
  C4 
  C5 
  C6 
  C7 
  C8 
  C9 
  C10 
  C11 
  C12 
  C13 
  C14 
  C15 
  C16 
Chapter Three 
_________________________________________________________________________________________________________________________________________________________________________ 
 61 
All attempts at the direct conversion of ketone 155 into its unsaturated counterpart 136 
were unsuccessful, a situation that was attributed to the presence of the free hydroxyl 
group present in the substrate. The alcohol was converted into the corresponding benzoyl 
ester 156 (73%) using benzoyl chloride in the presence of TEA and catalytic amounts of 
DMAP. The structure of ester 156 was determined through various spectral analyses. So, 
for example, the IR spectrum of this compound exhibited strong C=O stretching bands at 
1732, 1645 and 1635 cm−1 arising from the ketone, benzoyl ester and lactam moieties, 
respectively, while the ESI mass spectrum displayed a (M + H) ion at m/z 406. The 1H-
NMR spectrum (see Figure 3-5) exhibited, inter alia, 7 protons in the downfield region 
(from 6.63 to 7.94 ppm) thus indicating the presence of two aromatic moieties. The 13C-
NMR spectrum (see Figure 3-6) exhibited 21 distinct carbon resonances with those 
appearing at δ 204.8, 165.9 and 161.8 ppm being assigned to the corresponding ketone, 
benzoyl ester and lactam carbonyls.  
 
______________________________________________________________________ 
 
 
Figure 3-5. 1H-NMR spectrum of compound 156 (recorded in CDCl3 at 400 MHz) 
______________________________________________________________________ 
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______________________________________________________________________ 
 
 
Figure 3-6. 13C-NMR spectrum of compound 156 (recorded in CDCl3 at 100 MHz) 
______________________________________________________________________ 
 
Compound 156 was subjected to a number of established dehydrogenation protocols, the 
most effective of which involved phenylselenylation of the derived TMS enol ether and 
oxidation of the selenide so-formed with sodium metaperiodate in wet THF. This was 
followed by thermolysis of the ensuing selenoxide. By such means, the expected 
cycloalkenone 157 appeared to be produced (and in ca. 62% yield) as judged by the 
modest amounts of spectral data that could be obtained on the small amounts of this 
material. Unfortunately, at the time of submission of this thesis the insufficient material 
was available to allow for the completion of a total synthesis of compound ent-101. 
Nevertheless, it now seems possible that compound 157 can be carried forward to (+)-
lycorine (ent-101) by exploiting the methodologies used in the closing stages of the 
Tomioka’s synthesis. 
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3.3 Conclusion  
 
A chemoenzymatic total synthesis of (+)-lycorine (ent-101) that began with the 
homochiral fermentation product 3c seems close to being realized. A one-pot and free-
radical-based reductive cyclisation reaction was successfully employed in the 
construction of the pyrrolidine D-ring while the necessary stereo-control was achieved by 
employing a bulky TBDPS-ether residue in close proximity to the product radical and 
such that this ensured delivery of the hydrogen atom to the b-face of the developing 
lycorine framework. Work aimed at exploiting such selective processes in other settings 
are currently being explored. 
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4.1 Overview 
 
4.1.1 Background 
 
The flowering plant Narcissus serotinus L., as shown in Figure 4-1, is a species of the 
genus narcissus (daffodils) belonging to the Amaryllidaceae family.[1a] It is encountered 
in extremely dry coastal regions growing in calcareous sandy soil or maquis shrubland 
all over the southern Mediterranean. In addition to its ornamental value, the plant has 
served as a source of herbal medicines since ancient times.[1b] As part of a modern and 
comprehensive biological evaluation of the alkaloids found in this plant, narseronine was 
described by Bastida and his colleagues in 2010.[1] In particular, they reported the 
extraction and purification of narseronine from the fresh aerial parts and bulbs of N. 
serotinus L. and its structure was proposed on the basis of extensive spectroscopic 
studies.[1,2] Unfortunately, the specific rotation of this natural product was not reported 
and so any efforts directed toward the total synthesis of this compound should allow for 
access to either enantiomeric form (see Figure 4-1).  
 
______________________________________________________________________ 
                            
Figure 4-1. N. serotinus L and the structures of (−)- and (+)-forms of narseronine (29 and ent-29, 
respectively, as determined by synthesis) 
______________________________________________________________________ 
 
The unsaturated d-lactone contained in narseronine has been recognized as an important 
structural feature and a challenge associated with the assembly of the natural product. 
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Although, no specific biological evaluation of narseronine has been reported to date, 
structurally similar alkaloids display useful biological activities[3] including antifungal, 
antitumor and apoptosis-inducing effects.  
 
4.1.2 The Schwartz/Banwell Synthesis of (−)-Narseronine (29)  
 
In order to secure enough material for biological evaluation and to also confirm its 
assigned structure, an enantioselective total synthesis of (−)-narseronine (29)[4] was 
developed by Schwartz and Banwell in 2011. The opening stages of their synthesis are 
shown in Scheme 4-1 and exploited chemistry developed by these same researchers 
during the course of establishing a total synthesis of nobilisitine A.[5] The cis-1,2-
dihydrocatechol 3c was used as the starting material and was first converted, by standard 
methods and in 93% yield, into the well-known acetonide 158.[6] The latter compound 
was then treated with m-chloroperbenzoic acid (m-CPBA) and thus forming, through both 
regio- and stereo-selective epoxidation of the more electron-rich (non-brominated) 
double bond, epoxide 159 (95%). Regioselective nucleophilic addition of the in situ 
generated acetonitrile anion to this epoxide resulted in the formation of g-hydroxynitrile[7] 
160 (96%), which was subjected to a Barton-McCombie deoxygenation reaction.[8] The 
readily derived xanthate ester 161 (94%) was treated with tri-n-butyltin hydride in the 
presence of the radical initiator AIBN and the desired methylene-containing derivative 
162 was thereby obtained in 82% yield over the two steps involved. Subjection of 
compound 162 to Suzuki-Miyaura cross-coupling[9] conditions with boronate ester 140[5,7] 
then gave the key arylcyclohexene 163[5,7] in 75% yield. The nitrile moiety within 
coupling product 163 was treated with molecular hydrogen at 6000 KPa in the presence 
of an excess of Raney-cobalt.[10] and by such means a chemoselective reduction reaction 
took place to give the 1º-amine 164. 
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______________________________________________________________________ 
 
Scheme 4-1. Reaction conditions: (a) 2,2-DMP, p-TsOH•H2O, acetone, 18 °C, 1 h, 93%; (b) m-
CPBA, DCM, −5 °C, 16 h, 95%; (c) n-BuLi, acetonitrile, THF, −75 to −60 °C, 1.5 h, 96%; (d) 
NaH, CS2, MeI, THF, 0 to 18 °C, 1.5 h, 94%; (e) n-Bu3SnH, AIBN, benzene, 80 °C, 1.5 h, 82%; 
(f) PdCl2(dppf)•CH2Cl2, TEA, microwave irradiation, THF/H2O (9:1 v/v), 90 °C, 1.5 h, 75%; (g) 
H2 (6000 KPa), Raney-cobalt, MeOH (NH3 sat.), 45 °C, 2 h. 
______________________________________________________________________ 
 
This somewhat intractable amine was carried forward to the target compound 29 by the 
route shown in Scheme 4-2. Specifically, substrate 164 was reacted with Alloc-Cl in the 
presence of pyridine and the resulting carbamate then N-methylated with a combination 
of LiHMDS and methyl iodide. This gave the expected carbamate 165 in 88% yield (from 
nitrile 163). Sequential treatment of compound 165 with aqueous acetic acid (to effect 
cleavage of the acetonide residue) then LiHMDS (to effect lactonisation) gave the desired 
compound 166 in 77% yield. Irvine-Purdie methylation[11] of the free hydroxyl group 
within this compound followed by saponification of the lactone residue then gave the 
hydroxyl-acid 167 in 68% yield. Treatment of compound 167 under Swern oxidation 
conditions[12] not only effected the oxidation of the associated 2º-alcohol to the 
corresponding ketone but also formation of the methylthiomethyl ester of the acid moiety 
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and so delivering the keto-ester 168 (48%). Treatment of compound 168 with Pd(PPh3)4 
and an excess of dimedone[13] under standard conditions for cleaving Alloc-groups then 
provided the target compound (−)-narseronine (29) in 82% yield and as a crystalline solid 
that was subjected to single-crystal X-ray analysis. Presumably the conversion 168 ® 29 
proceeded through initial formation of enone 169 that engaged in a spontaneous 
intramolecular hetero-Michael addition reaction. The intermediate enolate underwent an 
intramolecular acylation reaction involving the pendant ester moiety and thus forming the 
unsaturated lactone unit associated with narseronine. All the spectral data acquired on 
product 29 matched those reported by Bastida and co-workers for the natural product 
narseronine. 
______________________________________________________________________ 
 
Scheme 4-2. Reaction conditions: (a) i) Alloc-Cl, py., 0 °C, 0.25 h, 88% from 163; ii) LiHMDS, 
MeI, −78 to 18 °C, 1 h, 98%; (b) i) AcOH/H2O (4:1 v/v), 50 °C, 0.6 h; ii) LiHMDS, THF, −78 °C, 
0.33 h, 77% over two steps; (c) i) Ag2O, MeI, acetonitrile, reflux, 12 h, 72%; ii) NaOH, THF/H2O 
(1:1 v/v), 18 °C, 0.5 h, 94%; (d) DMSO, oxalyl chloride, DCM, −78 °C, 1.8 h, 48%; (e) dimedone, 
Pd(PPh3)4, THF, 18 °C, 0.17 h, 82%. 
______________________________________________________________________ 
Since the absolute configuration of narseronine could not be established for the reasons 
described above, the synthesis of compound ent-29 was considered important. This is 
because both enantiomers and their respective precursors could then be subjected to 
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biological evaluation. Accordingly, the objective of research work described in the 
remaining part of this chapter was the preparation of the other enantiomeric form of 
narseronine (viz. ent-29). Given the demonstrated utility of the cis-1,2-dihydrocatechols 
in the enantiodivergent synthesis of a range of target compounds, the homochiral 
compound 3c was thought to be the most appropriate starting material for the present 
purpose.   
 
4.2 Previous Examples of Enantiodivergent Syntheses Using cis-1,2-Dihydrocate- 
chol 3c 
 
In 1990 Hudlicky and co-workers reported concise syntheses of both enantiomeric forms 
of the natural product pinitol[14] from the enzymatically-derived cis-1,2-dihydrocatechol 
3c (see Scheme 4-3). In reporting this work the concept of enantiodivergent synthesis[15] 
was articulated and emphasized that “with proper consideration of symmetry, both 
enantiomers may become available from a single isomer generated by biocatalytic 
means.”[15] The asymmetric syntheses of (−)- and (+)-pinitol started with the conversion 
of diol 3c into the corresponding and well-known acetonide 158 that was subjected to 
epoxidation with m-CPBA thus resulting in the exclusive formation of epoxide 159 (80%). 
This compound was then subjected to a methanolysis/dehalogenation sequence to give 
olefin 170 in 76% yield over the two steps involved. Dihydroxylation of compound 170 
(63%) under the UpJohn oxidation conditions (using OsO4/NMO)[16] gave a single diol 
and acid-catalyzed hydrolysis of the associated acetonide unit then gave (−)-pinitol (171) 
(quantitative). The derived spectral data as well as specific rotation were in excellent 
agreement with the literature values.[17] In contrast to the foregoing sequence, when 
acetonide 158 was first treated under the UpJohn oxidation conditions then diol 172 (85%) 
was obtained as the exclusive product of this reaction. Reduction of the cycloalkenyl 
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bromide residue within this last compound using LAH smoothly afforded the 
corresponding dehalogenated olefin (85%) that reacted with m-CPBA to give epoxy-diol 
173 in 86% yield. Regioselective methanolysis of compound 173 followed by acetonide 
group cleavage then gave (+)-pinitol (ent-171) (90%). The NMR, IR and MS spectral data 
derived from this material matched those previously reported for (+)-pinitol.[17] 
Significantly, of course, the specific rotation of this last compound was of the same 
magnitude but of opposite sign to that recorded for its enantiomer (viz. 171).  
______________________________________________________________________ 
 
Scheme 4-3. Reaction conditions: (a) 2,2-DMP, p-TsOHH2O, acetone, rt, 93%; (b) m-CPBA, 
DCM, 80%; (c) MeOH, Al2O3, 89%; (d) LiAlH4, THF, 85%; (e) OsO4, NMO, H2O, acetone, 63%; 
(f) aq. HCl, acetone, quantitative. 
______________________________________________________________________ 
 
Given the related research undertaken by the Banwell Group[18] enantiodivergent 
syntheses can now be defined as the generation of either enantiomeric form of a given 
target compound from the same enantiomeric form of starting material. 
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4.3 The Total Synthesis of (+)-Narseronine (ent-29) 
 
4.3.1 Retrosynthetic Analysis	
A possible approach to (+)-narseronine (ent-29) that would use cis-1,2-dihydrocatechol 
3c as starting material and exploit some of the author’s earlier work on approaches to (+)-
lycorine (ent-29) is shown (in retrosynthetic form) in Scheme 4-4. It was thought that the 
target molecule ent-29 could be obtained through N- and O-dimethylation of compound 
174 that should be itself accessible through manipulations (e.g. deprotection and 
inversion of the 2º-alcohol so-obtained) of the TBDPS-ether 175, the product of the 
oxidative free radical cyclisation of amine 138 as described in Chapter Three. To remind 
the reader, the 1º-amine 138 could be obtained by a four-step sequence that included a 
Suzuki-Miyaura cross-coupling reaction of boronate ester 140 with diol 139, a readily 
prepared derivative (see Chapter Three) of the homochiral cis-1,2-dihydrocatechol 3c.  
______________________________________________________________________ 
 
Scheme 4-4. Retrosynthetic analysis of (+)-narseronine (ent-29) leading to the identification of 
chiron 3c as possible starting material 
______________________________________________________________________ 
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4.3.2 Synthesis of the Key Intermediate 150	
 
The implementation of the synthetic plan defined immediately above requires the 
conversion of 1º-amine 138 into pyrrolidine 176. This proved to be fairly straightforward 
and involved the reaction sequence shown in Scheme 4-5 (with NBS being used instead 
of NCS so as to obtain compound 150 exclusively and in a higher yield).  
 
______________________________________________________________________ 
 
Scheme 4-5. Reaction conditions: (a) i) NCS, benzene (0.004 M), 22 °C, 0.5 h; ii) AIBN (0.04 
mol equiv.), n-Bu3SnH (1.2 mol equiv.), benzene, 80 °C, 6 h, 65% over two steps; (b) NBS, 
benzene (0.03 M), 22 °C, 0.5 h; ii) AIBN (0.13 mol equiv.), n-Bu3SnH (1.3 mol equiv.), benzene, 
80 °C, 1.5 h, 83% over two steps; (c) TBAF, THF, 22 °C, 18 h, 95%. 
______________________________________________________________________ 
 
In the opening step, NBS was added to a 0.03 M solution of 1º-amine 138 in benzene at 
room temperature (22 °C) and so generating the corresponding N-bromoamine. AIBN (13% 
mole equiv.) was then added to the reaction mixture, followed by the addition, over 0.83 
h, of a benzene solution of tri-n-butyltin hydride to the refluxing reaction mixture. As a 
result, compound 150 was obtained in 83% yield. Given the amorphous nature of this 
product it was subjected to the treatment with TBAF and the corresponding and 
crystalline 2°-alcohol 176 was obtained in 95% yield. Extensive spectroscopic analysis 
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of this product, including through single-crystal X-ray analysis (see Figure 4-2 for the 
derived ORTEP), served to confirm the illustrated structure. 
______________________________________________________________________ 
 
Figure 4-2. ORTEP derived from the single-crystal X-ray analysis of compound 176 with 
labelling of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. 
Hydrogen atoms are drawn as circles with small radii. 
______________________________________________________________________ 
 
The conversion of 1º-amine 138 into compound 150 via an oxidative free radical 
cyclisation process that stands in contrast to the outcomes observed in the formation of 
compound 151(see Page 58) from the same starting material under similar conditions. A 
possible mechanism for the formation of the oxidative cyclisation product 150 is shown 
in Scheme 4-6. Thus, the initial step involves the formation of the N-bromo-derivative of 
compound 138 (through halogen atom transfer from NBS) and the derivative 177 then 
reacts with the tri-n-butyltin free radical to give the corresponding N-centered radical (and 
tri-n-butyltin bromide). This last species then engages in a 5-exo-trig cyclisation reaction 
to yield the corresponding tetracyclic and relatively stable benzylic radical (viz. 178) that 
undergoes hydrogen atom abstraction (by a tri-n-butyltin free radical that is readily 
generated from the tri-n-butyltin hydride because of the relatively high concentration of 
AIBN used) and thereby establishing the conjugated C=C bond observed in product 150 
(and simultaneously regenerating the tri-n-butyltin hydride that participates in the next 
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cycle of the radical chain process). The presence of the a-configured bulky –OTBDPS 
facilitates the loss of oxymethine proton which is of b-configuration other than the 
azamethine one. 
 
______________________________________________________________________ 
 
Scheme 4-6. Possible mechanism of the oxidative free-radical cyclisation reaction associated 
with the conversion 138 ® 150 
______________________________________________________________________ 
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4.3.3 Completion of the Total Synthesis of (+)-Narseronine (ent-29) 	
 
Any completion of the total synthesis of (+)-narseronine (ent-29) from compound 176 
requires inversion of configuration at C5 as well as N- and O-dimethylation at the relevant 
centers. The first of these requirements was met by selectively oxidizing (see Scheme 4-
7) alcohol 176 (95%) to the corresponding ketone 179 (78%) using a large excess of 
MnO2. Luche reduction[19] of compound 179 then led, in an exclusive manner, to the C5 
epimer of compound 176, namely alcohol 174, which was obtained in high yield. The 
stereoselectivity of this reduction process presumably arises from the steric effects 
imposed by the adjacent and b-orientated pyrrolidine D-ring. This ensures that the 
hydride ion is delivered to the a-face of the ketone carbonyl. Whereas the Mitsunobu 
inversion was ignored regarding this process because competitive reactions would happen 
to the 2º-amine. 
______________________________________________________________________ 
 
Scheme 4-7. Reaction conditions: (a) MnO2, DCM, 30 °C, 22 h, 78%; (b) NaBH4, CeCl3•7H2O, 
MeOH, −78 °C, 0.25 h, 99%.  
______________________________________________________________________ 
 
The 1H-NMR, 13C-NMR, IR and LR/HRMS spectral data obtained on product 176 were 
entirely consistent with the illustrated structure but this was finally confirmed by the 
single-crystal X-ray analysis. The derived ORTEP is shown in Figure 4-3.  
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______________________________________________________________________ 
 
Figure 4-3. ORTEP derived from the single-crystal X-ray analysis of compound 174 with 
labelling of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. 
Hydrogen atoms are drawn as circles with small radii. 
______________________________________________________________________ 
 
The necessary N- and O-dimethylation of aminoalcohol 174 required to generate (+)-
narseronine (ent-29) proved to be a difficult transformation. It was observed that the 2º-
amine was more reactive than the 2º-alcohol under Irvine-Purdie[11] and several other 
conditions when methyl iodide and various bases (e.g. TEA, K2CO3, KOH, NaH, 
LiHMDS) were used. In such instances only the N-methylated derivative was obtained. 
Eventually, it was established that, as shown in Scheme 4-9, when a THF solution of 
compound 174 maintained at 0 °C was treated successively with ca. 4.0 molar equiv. of 
potassium hydride and 8.0 molar equiv. of methyl iodide then a relatively clean N,O-
bismethylation reaction took place, finally providing (+)-narseronine (ent-29) in 83% 
yield after chromatographic purification. The 1H-NMR and 13C-NMR spectral data 
derived from this material matched those recorded earlier[4] for its enantiomer, assigned 
as (−)-narseronine (29), but final confirmation of its structure followed from a single-
crystal X-ray analysis (the derived ORTEP is shown in Figure 4-5). The specific rotation 
of this compound was +21.0º (c 0.3, CDCl3) as compared with a value of −25.4º (c 1.6, 
CDCl3) recorded for its enantiomer.[4] 
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______________________________________________________________________ 
 
Scheme 4-9. Reaction conditions: (a) KH, MeI, THF, 0 to 22 °C, 4 h, 83%. 
______________________________________________________________________ 
______________________________________________________________________ 
 
Figure 4-5. ORTEP derived from the single-crystal X-ray analysis of compound ent-29 with 
labelling of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. 
Hydrogen atoms are drawn as circles with small radii. 
______________________________________________________________________ 
 
Comparisons of the relevant 1H-NMR (see Table 4-1) and 13C-NMR (see Table 4-2) 
spectral data sets acquired on compound ent-29 with those reported for both the 
synthetically-derived (–)-narseronine (29)[4] and the natural product revealed excellent 
agreement except for a minor discrepancy observed in the 13C-NMR spectra. In particular, 
the signal reported at d 111.5 ppm in the spectrum of the synthetically-derived (–)-
enantiomer 29 seems at odds with the one observed at d 108.5 ppm in the corresponding 
spectrum of (+)-narseronine (ent-29). This difference is attributed to the differing 
acidities of the media (i.e., base-filtered CDCl3 or CDCl3 as purchased) in which the two 
samples were analyzed. 
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Table 4-1. Comparison of the 1H-NMR spectroscopic data recorded for synthetically-
derived (–)- and (+)-narseronine with the natural product 
 
 
1H-NMR Spectra Data 
(–)-Narseroninea (+)-Narseroninea Narseronineb 
7.68, s, 1H 7.67, s, 1H 7.66, s, 1H 
7.28, s, 1H 7.28, s, 1H 7.29, s, 1H 
6.13, d, J = 1.2 Hz, 1H 
6.11, d, J = 1.2 Hz, 1H 
6.13, m, 2H 6.12, d, J = 1.2 Hz, 1H 
6.10, d, J = 1.2 Hz, 1H 
4.22, t, J = 6.0 Hz, 1H 4.22, t, J = 6.0, 1H 4.22, t, J = 6.1 Hz, 1H 
3.91, d, J = 7.0 Hz, 1H 3.82, br s, 1H 3.94, d, J = 6.4 Hz, 1H 
3.57, s, 3H 3.57, s, 3H 3.57, s, 3H 
3.07, dt, J = 11.0 and 7.6 Hz, 
1H 
3.07, m, 1H 3.05, dt, J = 11.0 and 7.6 Hz, 
1H 
2.78, m, 1Hc 2.78, m, 1H 2.81, m, 1H 
2.63, m, 1Hc 2.64, m, 1H 2.64, m, 1H 
2.43, s, 3H 2.44, s, 3H 2.41, s, 3H 
2.23-2.10, complex m, 2H 2.25-2.10, complex m, 2H 2.22-2.13, complex m, 2H 
2.03, dt, J = 13.0 and 6.0 Hz, 
1H 
2.01, m, 1H 2.01, dt, J = 13.5 and 5.5 Hz, 
1H 
1.89, ddd, J = 13.0, 8.0 and 
4.4 Hz, 1H 
1.90, m, 1H 1.90, ddd, J = 12.6, 8.3 and 
4.2 Hz, 1H 
a Data recorded in base-filtered CDCl3 at 400 MHz; b Data recorded in CDCl3 as purchased 
at 500 MHz; c The chemical shift of this resonance varied somewhat from run-to-run. 
 
Table 4-2. Comparison of the 13C-NMR spectroscopic data recorded for synthetically-
derived (–)- and (+)-narseronine with the natural product 
 
 
13C-NMR Spectra Data 
(–)-Narseroninea (+)-Narseroninea Narseronineb 
161.5  161.5  161.5  
153.5  153.7  153.8  
152.3  152.7  152.9   
148.1   148.3  148.4  
135.1  135.2  135.1  
116.3   116.4  116.4  
111.5c  108.5c  110.9c  
107.6  107.8  107.9  
103.1  103.3  103.3  
102.2  102.4  102.4  
74.8  75.0  75.0  
61.9  62.0  61.7  
58.0  58.2  58.3  
54.1  54.3  54.3  
42.1  42.1  41.8  
34.7  35.0  35.1  
31.2  31.4  31.4  
29.3  29.5  29.6  
a Data recorded in base-filtered CDCl3 at 100 MHz; b Data recorded in CDCl3 as purchased 
at 125 MHz;c The different chemical shift of this resonance was attributed to the differing 
acidity of the media in which the sample was analyzed.  
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The 1H-NMR spectral data derived from ent-29 (see Table 4-1) were completely 
consistent with the assigned structure. For instance, the two most obvious two signals 
observed at δ 2.43 and 3.57 ppm are assigned to the N-methyl and O-methyl groups, 
respectively. The resonance due to the methine proton on the carbon carrying the methoxy 
group resonates at δ 4.22 pm and this shows couplings (t, J = 6.0 Hz) arising through 
three-bond interactions with the methylene protons of the adjacent sp3-hybridised carbon. 
The resonance at δ 3.82 ppm is assigned to the methine proton of the ring-junction carbon 
carrying the pyrrolidine nitrogen. The 13C-NMR spectral data (see Table 4-2) exhibits 
eighteen distinct carbon resonances with that appearing at δ 161.5 ppm being assigned to 
the lactone carbonyl and the eight resonances due to the conjugated π system appearing 
at δ 153.7, 152.7, 148.3, 135.2, 116.4, 108.5, 107.8 and 103.3 ppm, respectively. The 
resonance observed at 102.4 pp is assigned to the carbon of the methylenedioxyl group. 
 
As a further indication of the difficulties associated with the N,O-bismethylation process 
described above, on treating aminoalcohol 174 with ca. 10.0 mole equiv. silver(I) oxide 
in neat methyl iodide (that thus served as both reagent and solvent) at 50 °C then a 
complex mixture of products was obtained from which a small amount of the crystalline 
but rather unstable compound 182 was obtained. Its structure was established by single-
crystal X-ray analysis (see Figure 4-4 for the derived ORTEP). Compound 182 
presumably arises through (see Scheme 4-8) an initial two-fold N-methylation of 
substrate 174 that produces the methiodide salt 180. Fragmentation of this last species 
presumably then occurs in the illustrated manner to give intermediate 181 and then, after 
proton loss, the observed product 182.[20]  
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Figure 4-4. ORTEP derived from the single-crystal X-ray analysis of compound 182 with 
labelling of selected atoms. Anisotropic displacement ellipsoids display 30% probability levels. 
Hydrogen atoms are drawn as circles with small radii. 
______________________________________________________________________ 
______________________________________________________________________ 
 
 
Scheme 4-8. Reaction conditions: (a) Ag2O, MeI, 50 °C, 16 h. 
______________________________________________________________________ 
 
 
 
 
  O1 
  O2 
  O3 
  O4 
  O5 
  N1   C1 
  C2 
  C3 
  C4 
  C5 
  C6 
  C7 
  C8 
  C9 
  C10 
  C11 
  C12 
  C13 
  C14 
  C15 
  C16 
  C17 
  C18 
N O
O
O
O
OH
I
O
O
O
O
OH
NMe2
I H
-AgI and -H2O
NH O
O
O
O
OH
O
O
O
O
OH
NMe2a
174                                                                                                182
180                                        181
Ag2O
Chapter Five 
_________________________________________________________________________________________________________________________________________________________________________ 
 85 
4.4 Conclusion 
 
The ability to effect syntheses of both (−)-narseronine (29)[4] and (+)-narseronine (ent-29) 
from the cis-1,2-dihydrocatechol 3c serves to further emphasize the utility of such 
systems as starting materials in chemical synthesis. In this instance, the capacity for 
enantiodivergence arose through the generation of the isomeric nitriles 160 and 142 (see 
Scheme 4-10). The stereochemistries at C5 in these compounds determined the 
orientations (a or b) of the derived pyrrolidine D-rings in the product enantiomers (−)- 
and (+)-narseronine, respectively. In the case of the approach to compound ent-29, and 
although inversion of configuration at C5 in compound 176 was required, the length of 
the reaction sequence is similar to that providing 29 (viz. 14 vs 15 steps), not least because 
of the more efficient means of introducing the methyl group at nitrogen in the synthesis 
described immediately above.  
 
______________________________________________________________________ 
 
Scheme 4-9. Key intermediates associated with the enantiodivergent syntheses of (+)- and (–)-
narseronine from cis-1,2-dihydrocatechol 3c 
______________________________________________________________________ 
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5.1 General Protocols 
 
Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded at 
room temperature in base-filtered CDCl3 on a Bruker spectrometer operating at 400 MHz 
for proton and 100 MHz for carbon nuclei. For 1H-NMR spectra, signals arising from the 
residual protioforms of the solvent were used as internal standards. 1H-NMR data are 
recorded as follows: δ chemical shift [multiplicity, coupling constant(s) J (Hz), relative 
integral] where multiplicity is defined as: s = singlet; d = doublet; t = triplet; q = quartet; 
m = multiplet or combinations of the above. The signal of the residual CHCl3 appearing 
at δH 7.26 and the central resonance of the CDCl3 “triplet” appearing at δC 77.1(6) were 
used to reference 1H- and 13C-NMR spectra, respectively. The signal of the residual 
CD3SOCD2H appearing at δH 2.50 and the central resonance of the (CD3)2SO “septet” 
appearing at δC 39.5(2) were used to reference 1H- and 13C-NMR spectra, respectively. 
The signal of the residual CD2HOD appearing at δH 3.31 and the central resonance of the 
CD3OD “septet” appearing at δC 49.0(0) were used to reference 1H- and 13C-NMR spectra, 
respectively. Infrared spectra (nmax) were recorded on a Perkin-Elmer UATR Two FTIR 
Spectrometer. Samples were analyzed as thin films on KBr plates. Low-resolution ESI 
mass spectra were recorded on a single quadrupole liquid chromatograph-mass 
spectrometer while high-resolution measurements were conducted on a time-of-flight 
instrument. Low- and high-resolution EI mass spectra were recorded on a magnetic-sector 
machine. Either high-resolution EI or ESI measurement provided the corresponding 
empirical formula of the sample as a substitute for Combustion Analysis. Melting points 
(using samples collected after flash chromatography) were measured on an Optimelt 
automated melting point system and are uncorrected.  
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Analytical thin layer chromatography (TLC) was performed on aluminum-backed 0.2 
mm thick silica gel 60 F254 plates as supplied by Merck. Eluted plates were visualized 
using a 254 nm UV lamp and/or by treatment with a suitable dip followed by heating. 
These dips included phosphomolybdic acid: ceric sulfate: sulfuric acid (conc.): water 
(37.5 g: 7.5 g: 37.5 g: 720 mL) or potassium permanganate: potassium carbonate: 5% 
sodium hydroxide aqueous solution: water (3 g: 20 g: 5 mL: 300 mL). Flash 
chromatographic separations were carried out following protocols defined by Still[1] with 
silica gel 60 (40-63 mm) as the stationary phase and using the AR- or HPLC-grade 
solvents indicated. Analytical HPLC was carried out on a 25 cm × 4.6 mm ID column 
packed with 5 µm extend C18 (Agilent, PN 770450-902) using an Agilent 1100 series 
quaternary pump and Diode Array Detector set at 210 nm. The mobile phase was 
water/methanol (95:5 v/v) flowing at 60 mL/h. Preparative HPLC was carried out on a 
15 cm × 19 mm ID column packed with 5 µm preparative C18 (Waters X Bridge, PN 
186002979) using a Waters 600E quaternary pump and 2996 Photodiode Array Detector 
set at 210 nm. The mobile phase was water/methanol (95:5 v/v) flowing at 600 mL/h. The 
HPLC-grade solvents were used in both the analytical and preparative HPLC experiments. 
Starting materials and reagents were generally available from the Sigma-Aldrich, Merck, 
TCI, Strem or Lancaster Chemical Companies and were used as supplied.  
 
Starting materials and reagents were generally available from the Sigma-Aldrich, Merck, 
TCI, Strem or Lancaster Chemical Companies and were used as supplied. Drying agents 
and other inorganic salts were purchased from the AJAX, BDH or Unilab Chemical 
Companies. Tetrahydrofuran (THF), diethyl ether, methanol and dichloromethane were 
dried using a Glass Contour solvent purification system that is based upon a technology 
originally described by Grubbs.[2] Where necessary, reactions were performed under a 
nitrogen atmosphere. 
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5.2 Experimental Procedures Related to Work Described in Chapter Two 
 
(1S,2R,3R,4S)-3,6-Dibromocyclohex-5-ene-1,2,4-triol (69) 
 
 
 
Following the method of Pinkerton,[3] a magnetically stirred solution of diene-diol 3c (3.0 
g, 15.7 mmol) in THF/H2O (80 mL of a 4:1 v/v mixture) maintained under an atmosphere 
of nitrogen at 0 °C was treated with NBS (3.08 g, 17.3 mmol, 1.1 mol equiv.) in small 
portions over 0.17 h. The resulting mixture was allowed to warm to 22 °C over 4 h then 
treated with Na2S2O3 (1.8 g). After a further 0.5 h NaCl (1.8 g) was added and the aqueous 
phase extracted with diethyl ether (3 × 50 mL). The combined organic phases were then 
dried (Na2SO4), filtered and concentrated under reduced pressure to give an amber-
colored oil. Flash chromatography (silica gel, 1:3 to 2:1 v/v ethyl acetate/n-hexane 
gradient elution) and concentration of the relevant fractions (Rf = 0.3 in 1:1 v/v ethyl 
acetate/n-hexane) under reduced pressure gave the title compound 69[3] (3.7 g, 83%) as a 
white, crystalline solid.  
 
1H-NMR [400 MHz, (CD3)2SO] δ 6.00 (d, J = 2.2 Hz, 1H), 5.52 (br s, 3H), 4.14 (dd, J = 
8.5 and 2.2 Hz, 1H), 4.05 (d, J = 4.0 Hz, 1H), 3.91 (dd, J = 11.5 and 8.5 Hz, 1H), 3.58 
(dd, J = 11.5 and 4.0 Hz, 1H).  
13C-NMR [100 MHz, (CD3)2SO] δ 134.9, 123.5, 73.3, 73.0, 70.4, 59.6. 
These data matched those reported[3] previously. 
 
OH
OH
Br
Br
OH
69
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(1R,2S,5S,6S)-3-Bromo-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol (68) 
 
 
 
Following the method of Pinkerton,[3] a magnetically stirred solution of compound 69 
(1.61 g, 5.6 mmol) in THF (15 mL) maintained under a nitrogen atmosphere at 0 °C was 
treated, in portions, with finely-ground sodium methoxide (1.21 g, 22.4 mmol, 4.0 mol 
equiv.). The resulting mixture was stirred at 22 °C for 3 h then treated with TLC-grade 
silica gel (2.0 g). After removing the solvent under reduced pressure the resulting free-
flowing solid was subjected to flash chromatography (silica gel, 1:3 to 3:1 v/v ethyl 
acetate/n-hexane gradient elution) and concentration of the relevant fractions (Rf = 0.2 in 
1:1 v/v ethyl acetate/n-hexane) under reduced pressure gave the title compound 68[3] (995 
mg, 86%) as a white, crystalline solid. 
 
1H-NMR [400 MHz, (CD3)2SO] δ 5.79 (d, J = 7.8 Hz, 1H), 5.76 (dd, J = 4.3 and 2.3 Hz, 
1H), 5.46 (d, J = 6.7 Hz, 1H), 4.33 (ddd, J = 6.7, 3.7 and 2.3 Hz, 1H), 4.24 (ddd, J = 7.8, 
4.3 and 2.2 Hz, 1H), 3.42 (dd, J = 4.4 and 3.7 Hz, 1H), 3.38 (dd, J = 4.4 and 2.2 Hz, 1H). 
13C-NMR [100 MHz, (CD3)2SO] δ 130.3, 123.9, 65.8, 65.4, 54.3, 54.1. 
These data matched those reported[3] previously. 
 
  
68
OH
Br
OH
O
Chapter Five 
_________________________________________________________________________________________________________________________________________________________________________ 
 93 
Benzoyl isocyanate (72) 
 
 
 
Following the method of Han,[4] a magnetically stirred solution of benzamide (1.21 g, 
10.0 mmol) in 1,2-dichloroethane (5 mL) maintained under a nitrogen atmosphere was 
chilled in an ice-bath then oxalyl chloride (2.1 mL, 24.0 mmol, 2.4 mol equiv.) was added 
dropwise. The resulting mixture was warmed to 22 °C and stirred at this temperature for 
0.5 h before being heated under reflux for 5 h. The cooled reaction mixture was then 
concentrated under reduced pressure to afford compound 72[4] (1.44 g, 98%) as a clear, 
colorless oil. 
 
1H-NMR (400 MHz, CDCl3) δ 8.07-8.04 (complex m, 2H), 7.65 (m, 1H), 7.50-7.45 
(complex m, 2H). 
13C-NMR (100 MHz, CDCl3) δ 165.2, 134.9, 131.4, 130.6, 128.9.    
IR νmax (KBr) 2233, 1698, 1599, 1398, 1228, 963, 696, 673, 602 cm−1. 
These data matched those reported[4] previously. 
 
 
  
O
N C
O
72
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(1S,2S,5S,6R)-4-Bromo-5-hydroxy-7-oxabicyclo[4.1.0]hept-3-en-2-ylbenzoylcarbamate 
(67) 
 
 
 
A magnetically stirred solution of epoxy-alcohol 68 (390 mg, 1.88 mmol) in THF (10 mL) 
maintained under a nitrogen atmosphere was cooled to −78 °C then treated, dropwise, 
with a freshly prepared solution of benzoyl isocyanate[4] (276 mg, 2.25 mmol, 1.2 mol 
equiv.) in THF (2.5 mL). The resulting mixture was stirred at 22 °C for 1 h then 
concentrated under reduced pressure to give an amorphous solid. Trituration of this 
material (diethyl ether/n-hexane) then gave benzoyl carbamate 67 (530 mg, 80%) as a 
white, crystalline solid. 
 
m.p. 106-108 °C. 
Optical rotation [α]D20 +0.127º (c 1.07, THF).  
HRMS (ESI, +ve) calcd for C14H1279BrNNaO5 [(M+Na)+] 375.9797, found 375.9792. 
1H-NMR [400 MHz, (CD3)2SO] δ 11.3 (s, 1H), 7.91-7.89 (complex m, 2H), 7.61 (m, 
1H), 7.52-7.48 (complex m, 2H), 6.01 (d, J = 7.7 Hz, 1H), 5.92 (dd, J = 4.4 and 2.2 Hz, 
1H), 5.56 (dd, J = 4.9 and 2.5 Hz, 1H), 4.37 (m, 1H), 3.65 (m, 1H), 3.55 (dd, J = 4.4 and 
2.7 Hz, 1H). 
13C-NMR [100 MHz, (CD3)2SO] δ 166.0, 151.0, 133.1, 132.7, 128.4, 128.3, 127.1, 124.9, 
69.7, 65.6, 54.0, 51.2.  
IR νmax (KBr) 3450, 3328, 1787, 1691, 1504, 1483, 1178, 974, 881, 771, 705, 573 cm−1. 
LRMS (ESI, +ve) m/z 378 and 376 [(M + Na)+, 97% and 100%, respectively]. 
OH
O
O
Br
NH
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(1S,2S,5S,6S)-4-Bromo-5-[(tert-butyldimethylsilyl)oxy]-7-oxabicyclo[4.1.0]hept-3-en-
2-yl benzoylcarbamate (74) 
 
 
 
A magnetically stirred solution of alcohol 67 (120 mg, 0.34 mmol) in dichloromethane 
(10 mL) maintained under a nitrogen atmosphere at 22 °C was treated, successively, with 
imidazole (35 mg, 0.51 mmol, 1.5 mol equiv.), TBS-Cl (66.4 mg, 0.44 mmol, 1.3 mol 
equiv.) and DMAP (8.3 mg, 0.07 mmol, 0.2 mol equiv.). The resulting mixture was stirred 
at 22 °C for 12 h before being quenched with sodium bicarbonate (3 mL of a saturated 
aqueous solution). The separated aqueous phase extracted with ethyl acetate (3 × 10 mL) 
and the combined organic phases were dried (Na2SO4), filtered and concentrated under 
reduced pressure. Flash chromatography (silica gel, 1:3 to 1:1 v/v ethyl acetate/n-hexane 
gradient elution) and concentration of the relevant fractions (Rf = 0.5 in 1:1 v/v ethyl 
acetate/n-hexane) under reduced pressure gave compound 74 (129 mg, 81%) as a white 
foam. 
 
Optical rotation [α]D20 +0.134º (c 2.8, CDCl3).  
HRMS (ESI, +ve) calcd for C20H2679BrNNaO5 [(M+Na)+] 490.0661, found 490.0656. 
1H-NMR (400 MHz, CDCl3) δ 8.66 (s, 1H), 7.89-7.87 (complex m, 2H), 7.58 (m, 1H), 
7.50-7.46 (complex m, 2H), 5.92 (dd, J = 4.7 and 2.0 Hz, 1H), 5.56 (dd, J = 4.7 and 2.6 
Hz, 1H), 4.48 (dd, J = 3.7 and 2.0 Hz, 1H), 3.65 (dt, J = 4.2 and 2.6 Hz, 1H), 3.50 (dd, J 
= 4.2 and 3.7 Hz, 1H), 0.96 (s, 9H), 0.22 (s, 3H), 0.19 (s, 3H). 
74
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13C-NMR (100 MHz, CDCl3) δ 165.1, 150.1, 133.3, 132.6, 129.0, 127.9, 127.1, 124.7, 
69.8, 68.0, 54.3, 51.5, 25.9, 18.4, 4.5, 4.3.  
IR νmax (KBr) 3290, 2955, 2929, 2857, 1766, 1511, 1485, 1186, 1109, 1094, 984, 922, 
838, 775, 705 cm−1.   
LRMS (ESI, +ve) m/z 492 and 490 [(M + Na)+, 100% and 97%, respectively]. 
 
(1S,2R,5R,6S)-3-Bromo-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diyl bis(4-nitrobenzoate) 
(80) 
 
 
 
A magnetically stirred solution of compound 68 (770 mg, 3.7 mmol) in THF (25 mL) 
maintained at 0 °C under a nitrogen atmosphere was treated, successively, with a solution 
of p-nitrobenzoic acid (1.55 g, 9.3 mmol, 2.5 mol equiv.) in THF (10 mL), a solution of 
PPh3 (2.44 g, 9.3 mmol, 2.5 mol equiv.) in THF (10 mL) and then a solution of DEAD 
(1.68 g, 9.7 mmol, 2.6 mol equiv.) in THF (10 mL). The resulting mixture was warmed 
to 22 °C over 2 h, stirred at this temperature for another 4 h then concentrated under 
reduced pressure to give a light-yellow oil. Flash chromatography (silica gel, 1:10 to 1:6 
v/v ethyl acetate/n-hexane gradient elution) and concentration of the relevant fractions 
(Rf = 0.7 in 1:3 v/v ethyl acetate/n-hexane) under reduced pressure gave compound 80 
(1.62 g, 86%) as a white, crystalline solid. 
 
 
80
O
O
O
O
O
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m.p. 168-170 °C. 
Optical rotation [α]D20 +0.40º (c 0.73, CHCl3).  
HRMS (ESI, +ve) calcd for C20H1379BrN2NaO9 [(M+Na)+] 526.9702, found 526.9698.   
1H-NMR (400 MHz, CDCl3) δ 8.35-8.27 (complex m, 8H), 6.49 (dd, J = 5.8 and 1.6 Hz, 
1H), 6.05 (m, 1H), 5.88 (ddd, J = 5.0, 3.3 and 1.6 Hz, 1H), 3.60 (m, 1H), 3.55 (m, 1H). 
13C-NMR (100 MHz, CDCl3) δ 163.9, 163.8, 151.1, 151.0, 134.5, 134.3, 131.3, 131.2, 
126.8, 123.9, 123.8, 123.3, 70.2, 66.8, 51.8, 49.6.      
IR νmax (KBr) 1729, 1608, 1526, 1348, 1327, 1255, 1094, 1015, 964, 872, 841, 717 cm−1. 
LRMS (ESI, +ve) m/z 529 and 527 [(M + Na)+, 97% and 100%, respectively].  
 
(1R,2R,5R,6S)-3-Bromo-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol (79) 
 
 
 
A magnetically stirred solution of ester 80 (2.53 g, 5.0 mmol) in methanol (20 mL) 
maintained under a nitrogen atmosphere was cooled in an ice-bath then treated with 
sodium methoxide (54 mg, 1.0 mmol, 0.2 mol equiv.). The resulting mixture was allowed 
to warm to 22 °C and stirred at this temperature for a further 0.17 h before being quenched 
with acetic acid (0.5 mL) then concentrated under reduced pressure to give a light-yellow 
oil. Flash chromatography (silica gel, 1:3 to 1:1 v/v ethyl acetate/n-hexane gradient 
elution) and concentration of the relevant fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/n-
hexane) under reduced pressure gave epoxy-alcohol 79 (960 mg, 93%) as a white, 
crystalline solid. 
 
79
OH
O
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Br
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m.p. 96-98 °C. 
Optical rotation [α]D20 +0.38º (c 0.54, CH3OH).  
HRMS (ESI, +ve) calcd for C6H779BrNaO3 [(M+Na)+] 228.9476, found 228.9476. 
1H-NMR [400 MHz, (CD3)2SO] δ 6.01 (d, J = 4.4 Hz, 1H), 5.82 (d, J = 8.1 Hz, 1H), 5.42 
(d, J = 7.2 Hz, 1H), 4.31-4.24 (complex m, 2H), 3.27 (s, 1H), 3.18 (s, 1H). 
13C-NMR [100 MHz, (CD3)2SO] δ 128.8, 125.7, 67.5, 63.3, 54.5, 51.7.  
IR νmax (KBr) 3291, 2891, 1652, 1031, 955, 805 cm−1. 
LRMS (ESI, +ve) m/z 303 (70%), 231 and 229 [(M + Na)+, 97% and 100%, respectively].  
 
(1S,2R,5R,6R)-4-Bromo-5-hydroxy-7-oxabicyclo[4.1.0]hept-3-en-2-ylbenzoylcarbama-
te (78) 
 
 
 
A magnetically stirred solution of epoxy-alcohol 79 (300 mg, 1.45 mmol) in THF (30 mL) 
maintained under a nitrogen atmosphere at −78 °C was treated, dropwise, with a freshly 
prepared solution of benzoyl isocyanate[5] (256 mg, 1.74 mmol, 1.2 mol equiv.) in THF 
(3 mL). The resulting mixture was stirred at 0 °C for 1 h then concentrated under reduced 
pressure to give an amorphous solid. Trituration of this material (diethyl ether/n-hexane) 
gave benzoyl carbamate 78 (436 mg, 85%) as a white, crystalline solid. 
 
m.p. 51-53 °C. 
Optical rotation [α]D20 +0.126º (c 1.4, CH2Cl2).  
HRMS (ESI, +ve) calcd for C14H1279BrNaNO5 [(M+Na)+] 375.9797, found 375.9792. 
78
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O
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1H-NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.84-7.81 (complex m, 2H), 7.62 (m, 1H), 
7.53-7.49 (complex m, 2H), 6.21 (dd, J = 5.4 and 1.7 Hz, 1H), 5.53 (m, 1H), 4.60 (m, 
1H), 3.53 (m, 1H), 3.45 (m, 1H), 3.00 (d, J = 8.0 Hz, 1H). 
13C-NMR (100 MHz, CDCl3) δ 165.8, 150.6, 133.5, 132.4, 129.3, 128.9, 128.1, 123.4, 
68.8, 67.4, 53.6, 49.2.    
IR νmax (KBr) 3286, 1770, 1706, 1513, 1489, 1280, 1191, 1047, 1007, 986, 706 cm−1.  
LRMS (ESI, +ve) m/z 378 and 376 [(M + Na)+, 97% and 100%, respectively], 290 (50%). 
 
(3aS,4S,5R,7aR)-6-Bromo-4-hydroxy-2-oxo-2,3,3a,4,5,7a-hexahydrobenzo[d]oxazol-5-
yl benzoate (81) and (3aR,4S,5R,7aR)-6-Bromo-2-oxo-2,3,3a,4,5,7a-hexahydrobenzo[d] 
oxazole-4,5-diyl dibenzoate (82)  
 
 
 
A magnetically stirred solution of carbamate 78 (23 mg, 0.065 mmol) in THF (1 mL) 
maintained at 0 °C under a nitrogen atmosphere was treated, successively, with potassium 
carbonate (19.3 mg, 0.14 mmol, 2.15 mol equiv.) and tetra-n-butylammonium chloride 
(3.6 mg, 0.013 mmol, 0.2 mol equiv.). The resulting mixture was stirred at 22 °C for 4 h 
before being diluted with diethyl ether (3 mL) and washed with brine (1 × 5 mL) then 
dried (Na2SO4), filtered and concentrated under reduced pressure. Flash chromatography 
(silica gel, 2% to 5% v/v ammonia-saturated methanol/ dichloromethane gradient elution) 
gave two fractions, A and B.  
 
81                                         82
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Concentration of fraction A (Rf = 0.2 in 5% v/v ammonia-saturated methanol/dichlorome-
thane) under reduced pressure gave compound 81 (9.5 mg, 32%) as a white, crystalline 
solid. 
 
m.p. 178-179 °C. 
Optical rotation [α]D20 +0.665º (c 0.23, THF).  
HRMS (ESI, +ve) calcd for C14H1279BrNaNO5 [(M+Na)+] 375.9797, found 375.9794. 
1H-NMR (400 MHz, CDCl3) δ 8.09-8.06 (complex m, 2H), 7.60 (m, 1H), 7.47-7.43 
(complex m, 2H), 6.52 (s, 1H), 6.39 (dd, J = 4.4 and 1.8 Hz, 1H), 5.72 (dt, J = 8.1 and 
1.7 Hz, 1H), 4.91 (ddd, J = 7.7, 4.3 and 1.4 Hz, 1H), 4.28 (s, 1H), 3.97 (t, J = 8.8 Hz, 1H), 
3.85 (dd, J = 9.1 and 7.7 Hz, 1H). 
13C-NMR (100 MHz, CDCl3) δ 166.1, 158.4, 133.8, 130.1, 128.9, 128.6, 127.6, 125.9, 
73.6, 72.7, 72.3, 55.0.  
IR νmax (KBr) 3320, 2924, 1723, 1314, 1264, 1116, 1092, 1024, 736, 708 cm−1. 
LRMS (ESI, +ve) m/z 378 and 376 [(M + Na)+, 98% and 100%, respectively], 202 (40%). 
 
Concentration of fraction B (Rf = 0.6 in 5% v/v ammonia-saturated methanol/dichloro-
methane) under reduced pressure gave compound 82 (7.1 mg, 31%) as a white, crystalline 
solid.  
 
m.p. 224-226 °C. 
Optical rotation [α]D20 +0.90º (c 0.58, THF).  
HRMS (ESI, +ve) calcd for C21H1679BrNNaO6 [(M+Na)+] 480.0059, found 480.0056. 
1H-NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.8 Hz, 2H), 7.93 (d, J = 7.8 Hz, 2H), 7.58-
7.54 (complex m, 2H), 7.43-7.39 (complex m, 4H), 6.56 (d, J = 3.9 Hz, 1H), 6.04 (d, J = 
6.7 Hz, 1H), 5.90 (s, 1H), 5.58 (m, 1H), 5.14 (dd, J = 8.0 and 3.9 Hz, 1H), 4.25 (m, 1H). 
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13C-NMR (100 MHz, CDCl3) δ 165.6, 165.5, 157.2, 134.1, 133.9, 130.2, 130.1, 128.8, 
128.7, 126.6, 128.5, 127.1, 125.6, 72.9, 72.8, 69.7, 53.0. 
IR νmax (KBr) 3274, 1756, 1730, 1713, 1260, 1125, 1089, 1068, 1027, 707 cm−1. 
LRMS (ESI, +ve) m/z 482 and 480 [(M + Na)+, 100% and 98%, respectively], 202 (40%). 
 
(3aR,4S,5R,7aR)-6-Bromo-2-oxo-2,3,3a,4,5,7a-hexahydrobenzo[d]oxazole-4,5-diyl 
dibenzoate (82) 
 
 
 
A magnetically stirred solution of carbamate 80 (23 mg, 0.065 mmol) in THF (1 mL) 
maintained under nitrogen at 0 °C was treated with potassium carbonate (19.3 mg, 0.14 
mmol, 2.15 mol equiv.) and tetra-n-butylammonium chloride (3.6 mg, 0.013 mmol, 0.2 
mol equiv.). The resulting mixture was stirred at 22 °C for 4 h before TEA (13 mg, 0.13 
mmol, 2.0 mol equiv.), DMAP (2 mg, 0.016 mmol, 0.25 mol equiv.) then benzoyl 
chloride (14 mg, 0.098 mmol, 1.5 mol equiv.) were added. After a further 6 h the reaction 
mixture was quenched with a sodium bicarbonate (1 mL of a saturated aqueous solution) 
and washed with brine (1 × 5 mL) before being dried (Na2SO4), filtered and concentrated 
under reduced pressure. Flash chromatography (silica gel, 2% to 5% v/v ammonia-
saturated methanol/dichloromethane gradient elution) and concentration of the relevant 
fractions (Rf = 0.6 in 5% v/v ammonia-saturated methanol/dichloromethane) under 
reduced pressure gave compound 82 (25 mg, 83%) as a white, crystalline solid. This 
material was identical, in all respects, with that obtained by the procedure described 
immediately above. 
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(1S,2R,3R,4S)-3-Bromo-6-iodocyclohex-5-ene-1,2,4-triol (88) 
 
 
 
Following the method of Pinkerton,[3] a magnetically stirred solution of diene-diol 3d 
(900 mg, 3.8 mmol) in THF/H2O (12.5 mL of a 4:1 v/v mixture) maintained under an 
atmosphere of nitrogen at 0 °C was treated with NBS (810 mg, 4.5 mmol, 1.2 mol equiv.) 
in small portions over 0.17 h. The resulting mixture was allowed to warm to 22 °C over 
1 h then treated with Na2S2O3 (800 mg). After a further 0.5 h, NaCl (800 mg) was added 
and the separated aqueous phase extracted with diethyl ether (5 × 20 mL). The combined 
organic phases were then dried (Na2SO4), filtered and concentrated under reduced 
pressure to give an amber-colored oil. Flash chromatography (silica gel, 1:3 to 3:1 v/v 
ethyl acetate/n-hexane gradient elution) and concentration of the relevant fractions (Rf = 
0.3 in 1:1 v/v ethyl acetate/n-hexane) under reduced pressure gave the title compound 
88[3] (1.18 g, 93%) as a white, crystalline solid.  
 
1H-NMR [400 MHz, (CD3)2SO] δ 6.22 (d, J = 2.4 Hz, 1H), 5.74 (d, J = 7.1 Hz, 1H), 5.62 
(d, J = 6.3 Hz, 1H), 5.39 (d, J = 7.6 Hz, 1H), 4.06-4.12 (complex m, 2H), 3.91 (dd, J = 
11.5 and 8.5 Hz, 1H), 3.58 (ddd, J = 11.5, 7.6 and 3.9 Hz, 1H).  
13C-NMR [100 MHz, (CD3)2SO] δ 142.6, 100.3, 76.1, 74.4, 70.2, 59.8. 
These data matched those reported[3] previously. 
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(1R,2S,5S,6S)-3-Iodo-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol (89) 
 
 
 
Following the method of Pinkerton,[3] a magnetically stirred solution of compound 88 
(1.2 g, 3.58 mmol) in THF (5 mL) maintained under a nitrogen atmosphere at 0 °C was 
treated, in portions, with sodium hydride (172 mg of a 60% suspension in mineral oil, 4.3 
mmol, 1.2 mol equiv.). The resulting mixture was stirred at 22 °C for 3 h then treated 
with TLC-grade silica gel (2.0 g). After removing the solvent under reduced pressure the 
resulting free-flowing solid was subjected to flash chromatography (silica gel, 1:3 to 3:1 
v/v ethyl acetate/n-hexane gradient elution) and concentration of the relevant fractions 
(Rf = 0.2 in 1:1 v/v ethyl acetate/n-hexane) under reduced pressure gave the title 
compound 89[3] (840 mg, 92%) as a white, crystalline solid. 
 
1H-NMR [400 MHz, (CD3)2SO] δ 6.00 (dd, J = 4.4 and 2.2 Hz, 1H), 5.72 (d, J = 7.8 Hz, 
1H), 5.36 (d, J = 5.9 Hz, 1H), 4.20 (dd, J = 5.9 and 2.8 Hz, 1H), 4.07 (dd, J = 7.8 and 2.7 
Hz, 1H), 3.29-3.33 (complex m, 2H). 
13C-NMR [100 MHz, (CD3)2SO] δ 138.2, 103.6, 67.1, 66.2, 54.2, 53.5. 
These data matched those reported[3] previously. 
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(1S,2R,5R,6S)-3-Iodo-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diyl bis(4-nitrobenzoate) (90) 
 
 
 
A magnetically stirred mixture of PPh3 (2.6 g, 9.8 mmol, 2.5 mol equiv.), DEAD (1.6 mL, 
10.1 mmol, 2.6 mol equiv.) and p-nitrobenzoic acid (1.6 g, 9.8 mmol, 2.5 mol equiv.) in 
THF (20 mL) was maintained under nitrogen atomsphere at 0 °C for 0.5 h then a solution 
of compound 89 (1.0 g, 3.9 mmol) in THF (20 mL) was added over 1 h. The resulting 
mixture was stirred at 0 °C for another 4 h then concentrated under reduced pressure to 
give a light-yellow oil. Flash chromatography (silica gel, 1:20 to 1:6 v/v ethyl acetate/n-
hexane gradient elution) and concentration of the relevant fractions (Rf = 0.7 in 1:3 v/v 
ethyl acetate/n-hexane) under reduced pressure gave compound 90 (1.91 g, 88%) as a 
white, crystalline solid. 
 
m.p. 130-131 °C. 
Optical rotation [α]D20 +0.05º (c 1.0, CH2Cl2).  
HRMS (ESI, +ve) calcd for C20H13127IN2NaO9 [(M+Na)+] 574.9564, found 574.9559. 
1H-NMR (400 MHz, CDCl3) δ 8.36-8.25 (complex m, 8H), 6.76 (dd, J = 5.0 and 1.6 Hz, 
1H), 6.02 (dd, J = 2.2 and 1.1 Hz, 1H), 5.77 (m, 1H), 3.55 (m, 1H), 3.53 (m, 1H). 
13C-NMR (100 MHz, CDCl3) δ 163.9, 163.8, 151.1(3), 151.0(7), 134.5(2), 134.4(8), 
134.3(7), 131.3(5), 131.2, 123.9(0), 123.8(6), 98.0, 72.4, 67.1, 51.3, 49.5.  
IR νmax (KBr) 1731,1526, 1349, 1258, 1095, 1014, 872, 841, 718 cm−1. 
LRMS (ESI, +ve) m/z 575 and 553 [(M + Na)+, 97% and 45%, respectively], 334 (100%). 
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 (1R,2R,5R,6S)-3-Iodo-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol (91) 
 
 
 
A magnetically stirred suspension of ester 90 (1.91 g, 3.45 mmol) in methanol (30 mL) 
maintained under an atmosphere of nitrogen at 22 °C was treated with ammonia-saturated 
methanol (5 mL). The resulting mixture was stirred at this temperature for 0.5 h then 
concentrated under reduced pressure to give a light-yellow oil. Flash chromatography 
(silica gel, 1:3 to 3:1 v/v ethyl acetate/n-hexane gradient elution) and concentration of the 
relevant fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/n-hexane) under reduced pressure gave 
epoxy-alcohol 91 (810 mg, 93%) as a white, crystalline solid. 
 
m.p. 99-100 °C. 
Optical rotation [α]D20 +0.04º (c 1.7, CH3OH).  
HRMS (EI, 70 eV) calcd for C6H7127IO3 (M+•) 253.9440, found 253.9438. 
1H-NMR [400 MHz, (CD3)2SO] δ 6.28 (dd, J = 5.0 and 1.4 Hz, 1H), 5.75 (d, J = 7.3 Hz, 
1H), 5.38 (d, J = 7.3 Hz, 1H), 4.23 (d, J = 8.4 Hz, 1H), 4.17 (m, 1H), 3.20-3.18 (complex 
m, 2H). 
13C-NMR [100 MHz, (CD3)2SO] δ 136.5, 103.6, 69.8, 63.9, 53.8, 51.6, 39.5.  
IR νmax (KBr) 3355, 1637, 1395, 1248, 1029, 946, 802 cm−1. 
LRMS (EI, 70 eV) m/z 254 (M+•, 30%), 127 (100%). 
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(3aR,4S,5R,7aR)-3-Benzoyl-6-iodo-2-oxo-2,3,3a,4,5,7a-hexahydrobenzo[d]oxazole-4,5-
diyl dibenzoate (96) 
 
 
 
A magnetically stirred solution of compound 91 (190 mg, 0.75 mmol) in dry THF (10 
mL) maintained under a nitrogen atmosphere at -78 °C was treated with a freshly 
prepared benzoyl isocyanate (76 mg, 0.52 mmol, 1.0 mol equiv.). The resulting mixture 
was stirred at 0 °C for 1 h before being concentrated under reduced pressure to give a 
white foam. This material was dissolved in THF (5 mL) and treated with K2CO3 (144 mg, 
1.1 mmol, 2.0 mol equiv.) and TBAC (29 mg, 0.11 mmol, 0.2 mol equiv.). The ensuing 
mixture was stirred at 22 °C for 2 h then TEA (181 µL, 1.3 mmol, 2.5 mol equiv.), DMAP 
(12 mg, 0.1 mmol, 0.2 mol equiv.) and benzoyl chloride (182 µL, 1.6 mmol, 3.0 mol 
equiv.) were added. After a further 6 h the reaction mixture was quenched with sodium 
bicarbonate (1 mL of a saturated aqueous solution) and washed with brine (1 × 5 mL) 
before being dried (Na2SO4), filtered and concentrated under reduced pressure. Flash 
chromatography (silica gel, 1:6 to 1:3 v/v ethyl acetate/n-hexane gradient elution) and 
concentration of the relevant fractions (Rf = 0.6 in 1:1 v/v ethyl acetate/n-hexane) under 
reduced pressure gave compound 96 (480 mg, 40%) as a white foam.  
 
Optical rotation [α]D20 +1.24º (c 1.7, CH2Cl2).  
HRMS (ESI, +ve) calcd for C28H20NNaO7 [(M+Na)+] 632.0182, found 632.0181. 
1H-NMR (400 MHz, CD3OD) δ 7.94 (d, J = 7.8 Hz, 2H), 7.88 (d, J = 7.8 Hz, 2H), 7.62 
(d, J = 7.8 Hz, 2H), 7.55 (m, H), 7.50-7.46 (complex m, 2H), 7.42-7.38 (complex m, 2H), 
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7.34-7.26 (complex m, 2H), 6.91 (d, J = 3.4 Hz, 1H), 6.09 (m, 1H), 6.03 (d, J = 5.1 Hz, 
1H), 5.19 (m, 1H), 2.01 (s, 3H), 5.14 (dd, J = 7.6 and 3.4 Hz, 1H). 
13C-NMR (100 MHz, CD3OD) δ 169.4, 165.3, 164.9, 152.1, 134.7, 133.9, 133.7, 133.0, 
132.0, 130.1, 130.0, 129.8, 128.7, 128.5, 127.9, 126.4, 101.6, 77.4, 71.9, 71.5, 68.4, 53.6. 
IR νmax (KBr) 1794, 1731, 1691, 1293, 1264, 1195, 1092, 1026, 709 cm−1. 
LRMS (ESI, +ve) m/z 632 [(M + Na)+, 45%]. 
 
N-[(1R,2R,5R,6S)-2,5,6-Trihydroxy-4-iodocyclohex-3-en-1-yl] acetamide (99) 
 
 
 
A magnetically stirred solution of compound 91 (190 mg, 0.75 mmol) in dry THF (15 
mL) maintained under a nitrogen atmosphere at -78 °C was treated with a freshly 
prepared benzoyl isocyanate (110 mg, 0.75 mmol, 1.0 mol equiv.). The resulting mixture 
was stirred at 0 °C for 1 h before being concentrated under reduced pressure to give a 
white foam. This material was dissolved in THF/H2O (5.5 mL of a 10:1 v/v mixture) and 
the resulting solution was treated with K2CO3 (210 mg, 1.5 mmol, 2.0 mol equiv.) and 
TBAC (42 mg, 0.15 mmol, 0.2 mol equiv.). After being stirred at 22 °C for 2 h, the 
reaction mixture was concentrated under reduced pressure and the residue thus obtained 
was dissolved in H2O/MeOH (10 mL of a 1:1 v/v mixture) containing NaOH (300 mg, 
7.5 mmol, 10.0 mol equiv.) and the resulting solution was heated under reflux for 2 h 
before being cooled then treated with HCl (1.0 M aqueous solution) so as to attain a pH 
of ~ 8.5. Ac2O (140 µL, 1.5 mmol, 2.0 mol equiv.) was then added to the reaction mixture 
and the ensuing mixture stirred for another 2 h before being concentrated under reduced 
OH
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pressure to give a light-yellow residue. Flash preparative HPLC (Waters X-Bridge C18 
column, 15 cm × 19 mm ID column, reverse phase, 95:5 v/v water/methanol elution, 600 
mL/h flow rate, detection at UV 210 nm) and concentration of the relevant fractions (Rt 
= 0.1 h) under reduced pressure gave the title compound 99 (160 mg, 80%) as a white 
foam. 
 
m.p. 58-59 °C. 
Optical rotation [α]D20 +0.04º (c 0.7, CH3OH).  
HRMS (ESI, +ve) calcd for C8H12127INNaO4 [(M+Na)+] 335.9709, found 335.9707. 
1H-NMR (400 MHz, CD3OD) δ 6.56 (dd, J = 5.6 and 1.8 Hz, 1H), 4.03 (m, 1H), 3.96 
(dd, J = 11.0 and 4.0 Hz, 1H), 3.89 (dd, J = 7.4 and 1.8 Hz, 1H), 3.78 (dd, J = 11.0 and 
7.4 Hz, 1H), 2.01 (s, 3H) (signals due to N–H and O–H group protons were not observed). 
13C-NMR (100 MHz, CD3OD) δ 173.7, 139.8, 110.3, 78.3, 71.4, 68.2, 54.3, 22.8.  
IR νmax (KBr) 3304, 2981, 1634, 1544, 1378, 1262, 1070, 953 cm−1. 
LRMS (ESI, +ve) m/z 336 [(M + Na)+, 20%], 85 (100%). 
 
Methyl (3R,4R,5S,6S)-4-acetamido-3,5,6-trihydroxycyclohex-1-ene-carboxylate (100) 
 
 
 
A magnetically stirred solution of compound 99 (94 mg, 0.3 mmol) in MeOH (5 mL) was 
treated with a stream of carbon monoxide for 0.25 h then TEA (0.17 mL, 1.2 mmol, 4.0 
mol equiv.) was added, followed by PPh3 (31.5 mg, 0.12 mmol, 0.4 mol equiv.) and 
Pd(OAc)2 (13.5 mg, 0.06 mmol, 0.2 mol equiv.). The resulting suspension was 
OH
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maintained under a carbon monoxide atmosphere while being heated at 40 °C for 6 h 
before cooling to ambient temperature. The reaction mixture was concentrated under 
reduced pressure to give an orange oil, followed by flash preparative HPLC (Waters X-
Bridge C18 column, 15 cm × 19 mm ID column, reverse phase, 95:5 v/v water/methanol 
elution, 600 mL/h flow rate, detection at UV 210 nm). Concentration of the relevant 
fractions (Rt = 0.09 h) under reduced pressure gave the title compound 100 (57 mg, 78%) 
as a white foam. 
 
m.p. 46-48 °C. 
Optical rotation [α]D20 –0.006º (c 1.05, CH3OH).  
HRMS (ESI, +ve) calcd for C10H15NNaO6 [(M+Na)+] 268.0797, found 268.0799. 
1H-NMR (400 MHz, CD3OD) δ 6.01 (dd, J = 4.7 and 1.3 Hz, 1H), 4.62-4.59 (complex 
m, 3H), 4.38-4.33 (complex m, 2H), 4.01 (dd, J = 9.8 and 4.3 Hz, 1H), 3.84 (dd, J = 9.8 
and 6.2 Hz, 1H), 3.78 (s, 3H), 2.01 (s, 3H) (signal due to N–H group proton was not 
observed). 
13C-NMR (100 MHz, CD3OD) δ 173.7, 168.3, 138.2, 135.2, 71.7, 71.6, 53.4, 52.4, 22.8.  
IR νmax (KBr) 3350, 2980, 2951, 1712, 1643, 1538, 1439, 1258, 1074, 1040 cm−1. 
LRMS (ESI, +ve) m/z 268 [(M + Na)+, 100%]. 
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5.3 Experimental Procedures Related to Work Described in Chapter Three 
 
(3aR,4R,5S,7aS)-4,7-Dibromo-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-
ol (141) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of compound 69 (3.70 
g, 12.9 mmol) in 2,2-dimethoxy-propane (40 mL) maintained under a nitrogen 
atmosphere at 0 °C was treated with p-toluenesulfonic acid (300 mg, 1.74 mmol, 0.13 
mol equiv.). The resulting mixture was warmed to 22 °C, stirred at this temperature for 2 
h, quenched with sodium bicarbonate (30 mL of a saturated aqueous solution) then 
extracted with ethyl acetate (3 × 30 mL). The combined organic phases were dried 
(Na2SO4), filtered and concentrated under reduced pressure to afford a light-yellow oil. 
Flash chromatography (silica gel, 1:4 v/v ethyl acetate/n-hexane elution) and 
concentration of the relevant fractions (Rf = 0.2 in 1:4 v/v ethyl acetate/n-hexane) under 
reduced pressure afforded bromohydrin 141[5] (4.94 g, 96%) as a white foam. 
 
1H-NMR (400 MHz, CDCl3) δ 6.36 (m, 1H), 4.68 (d, J = 5.1 Hz, 1H), 4.60 (m, 1H), 4.31-
4.26 (complex m, 2H), 2.97 (d, J = 12.0 Hz, 1H), 1.52 (s, 3H), 1.42 (s, 3H). 
13C-NMR (100 MHz, CDCl3) δ 131.6, 123.0, 111.8, 77.9, 76.2, 70.6, 49.4, 27.9, 26.3. 
These data matched those reported[5] previously. 
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2-{(3aS,4S,5R,7aS)-7-Bromo-4-hydroxy-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3] 
dioxol-5yl}acetonitrile (142) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of bromohydrin 141 
(5.15 g, 15.7 mmol) in THF (40 mL) maintained under a nitrogen atmosphere was cooled 
to 0 °C then treated with sodium hydride (720 mg of a 60% suspension in mineral oil, 
18.8 mmol, 1.2 mol equiv.). The resulting mixture was stirred at 0 °C for 0.5 h before 
being added, dropwise, to a magnetically stirred solution of acetonitrile (3.4 mL, 62.8 
mmol, 4.0 mol equiv.) and n-butyl lithium (18.8 mL of a 2.5 M solution in THF, 47.1 
mmol, 3.0 mol equiv.) in THF (60 mL) maintained at −78 °C. After 0.25 h the reaction 
mixture was quenched with NH4Cl (30 mL of a saturated aqueous solution) and the 
separated aqueous phase extracted with ethyl acetate (3 × 30 mL). The combined organic 
phases were washed with CuSO4 (1 × 50 mL of a 10% w/v aqueous solution) before being 
dried (Na2SO4), filtered and concentrated under reduced pressure to give a light-yellow 
oil. Flash chromatography (silica gel, 1:1 v/v ethyl acetate/n-hexane elution) and 
concentration of the relevant fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/n-hexane) under 
reduced pressure afforded nitrile 142[5] (3.98 g, 88%) as a gold-colored powder. 
 
1H-NMR (400MHz, CDCl3) δ 6.00 (d, J = 1.4 Hz, 1H), 4.64 (dd, J = 5.2 and 1.9 Hz, 1H), 
4.48 (dd, J = 5.2 and 2.3 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 2.77-2.73 (complex m, 2H), 
2.66-2.60 (complex m, 2H), 1.41 (s, 3H), 1.41 (s, 3H). 
13C-NMR (100 MHz, CDCl3) δ 129.0, 117.9, 78.4, 77.2, 70.2, 37.8, 27.5, 26.6, 19.7. 
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These data matched those reported[5] previously. 
 
O-{(3aS,4S,5R,7aS)-7-Bromo-5-(cyanomethyl)-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo 
[d][1,3] dioxol-4-yl}S-methyl carbonodithioate (143) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of compound 142 (2.11 
g, 7.3 mmol) in THF (45 mL) maintained under nitrogen was cooled to 0 °C and then 
treated with sodium hydride (350 mg of a 60% suspension in mineral oil, 8.8 mmol, 1.2 
mol equiv.). The resulting mixture was warmed to 22 °C over 0.5 h and then cooled again 
to 0 °C, treated with carbon disulfide (0.6 mL, 9.5 mmol, 1.3 mol equiv.), warmed to 
22 °C over 0.5 h, cooled again to 0 °C, treated with methyl iodide (0.6 mL, 9.5 mmol, 1.3 
mol equiv.) and then allowed to warm to 22 °C over a further 0.5 h. The reaction mixture 
was then quenched with NH4Cl (20 mL of a half-saturated solution) and the aqueous 
phase extracted with diethyl ether (3 × 30 mL). The combined organic phases were then 
washed with H2O (1 × 30 mL) before being dried (Na2SO4), filtered and concentrated 
under reduced pressure to give a light-yellow oil. Flash chromatography (silica gel, 1:9 
to 1:3 v/v ethyl acetate/n-hexane gradient elution) and concentration of the relevant 
fractions (Rf = 0.3 in 1:3 v/v ethyl acetate/n-hexane) under reduced pressure afforded 
xanthate 143[5] (2.50 g, 90%) as a gold-colored foam. 
 
1H-NMR (CDCl3, 400 MHz) δ 6.08 (d, J = 2.0 Hz, 1H), 5.91(dd, J = 10.2 and 2.0 Hz, 
1H), 4.71-4.65 (complex m, 2H), 3.27 (m, 1H), 2.62 (dd, J = 16.8 and 4.8 Hz, 1H), 2.62 
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(s, 3H), 2.45 (dd J = 16.8 and 7.8 Hz, 1H), 1.45 (s, 3H), 1.40 (s, 3H). 
13C-NMR (CDCl3, 100 MHz) δ 216.0, 128.2, 125.7, 117.1, 111.6, 78.8, 78.1, 74.1, 35.2, 
27.5, 26.8, 19.6. 
These data matched those reported[5] previously. 
 
2-{(3aS,5S,7aS)-7-Bromo-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-
yl}acetonitrile (139) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of xanthate 143 (2.50 
g, 6.6 mmol) in benzene (50 mL) was heated under reflux while being maintained under 
an atmosphere of nitrogen then treated with AIBN (90 mg, 0.66 mmol, 0.1 mol equiv.) 
and tri-n-butyltin hydride (2.0 mL, 7.9 mmol, 1.2 mol equiv.). The resulting mixture was 
heated under reflux for a further 3 h before being cooled to 22 °C and treated with NH4Cl 
(20 mL of a saturated aqueous solution). The separated aqueous phase extracted with 
diethyl ether (3 × 20 mL) and the combined organic phases were dried (Na2SO4), filtered 
and concentrated under reduced pressure to yield a yellow oil that was dissolved in 
acetonitrile (30 mL). The resulting solution was washed with pentane (3 × 20 mL) and 
then concentrated under reduced pressure to give a light-yellow oil. Flash 
chromatography (silica gel, 1:6 to 1:2 v/v ethyl acetate/n-hexane gradient elution) and 
concentration of the relevant fractions (Rf = 0.2 in 1:2 v/v ethyl acetate/n-hexane) under 
reduced pressure afforded bromide 139[5] (1.60 g, 87%) as a golden foam. 
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1H-NMR (400 MHz, CDCl3) δ 6.09 (m, 1H), 4.51-4.46 (complex m, 2H), 2.82 (m, 1H), 
2.46 (dd, J = 16.3 and 6.0 Hz, 1H), 2.41 (dd, J = 16.3 and 6.3 Hz, 1H), 2.31 (m, 1H), 1.64 
(m, 1H), 1.39 (s, 9H). 
13C-NMR (100 MHz, CDCl3) δ 131.9, 125.8, 117.5, 109.7, 76.1, 73.3, 30.5, 30.3, 27.4, 
26.4, 22.8. 
These data matched those reported[5] previously. 
 
6-Bromobenzo[d][1,3]dioxole-5-carbaldehyde (145) 
 
 
 
Following the method of Poli,[6] a magnetically stirred suspension of iron powder (2.46 
g, 44 mmol, 1.1 mol equiv.) in AcOH (30 mL) maintained under a nitrogen atmosphere 
was cooled in an ice-bath then treated with molecular bromine (3.7 mL, 71.2 mmol, 1.8 
mol equiv.). The resulting mixture was stirred at this temperature for a further 0.5 h before 
a solution of piperonal (144) (6.0 g, 40.0 mmol) in AcOH (30 mL) was added. After a 
further 0.5 h, another portion of molecular bromine (2.3 mL, 44.0 mmol, 1.1 mol equiv.) 
was added then the reaction mixture was stirred at 22 °C for 24 h before being diluted 
with CHCl3 (100 mL), washed with Na2S2O3 (5 × 30 mL of a saturated aqueous solution), 
Na2CO3 (3 × 30 mL of a 10% w/v aqueous solution) and brine (3 × 30 mL). The organic 
phase was dried (Na2SO4), filtered and concentrated under reduced pressure and 
crystallization (ethanol) of the solid thus obtained afforded aldehyde 145[6] as a white, 
crystalline solid (8.3 g, 91%). 
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1H-NMR (400 MHz, CDCl3) δ 10.17 (s, 1H), 7.35 (s, 1H), 7.06 (s, 1H), 6.08 (s, 2H). 
13C-NMR (100 MHz, CDCl3) δ 190.5, 153.5, 148.3, 128.2, 121.8, 113.4, 108.3, 102.9. 
These data matched those reported[6] previously. 
 
Methyl 6-bromobenzo[d][1,3]dioxole-5-carboxylate (146) 
 
 
 
Following the method of Håkansson,[7] a solution of NaClO2 (12.2 g, 134 mmol, 3.7 mol 
equiv.) and NaH2PO4H2O (32.5 g, 236 mmol, 6.5 mol equiv.) in H2O (100 mL) was 
added, dropwise, to a suspension of compound 145 (8.3 g, 36.2 mol) in acetone (100 mL) 
containing 2-methyl-2-butene (20 mL) while keeping the temperature below 30 °C. The 
resulting mixture was stirred vigorously for 2 h at 22 °C then treated with HCl (36% 
aqueous solution) so as to attain a pH of ~ 1 before being extracted with ethyl acetate (5 
× 100 mL). The combined organic phases were dried (Na2SO4), filtered and concentrated 
under reduced pressure to give a white solid that was immediately taken up in dry 
methanol (100 mL) containing concentrated H2SO4 (5 mL). The mixture thus obtained 
was stirred magnetically while being heated under reflux for 12 h before being cooled 
and diluted with H2O (100 mL) thus leading to the formation of a precipitate. This 
precipitate was collected by filtration and the mother liquors were partially concentrated 
under reduced pressure to produce a second crop of precipitate that was also collected by 
filtration. The combined solids were dissolved in dichloromethane (150 mL) as the 
solution thus obtained then washed with H2O (3 × 100 mL) and sodium bicarbonate (100 
mL of a saturated aqueous solution) before being dried (Na2SO4), filtered and 
146
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concentrated under reduced pressure to afford ester 146[7] (8.6 g, 92%) as a white, 
crystalline solid (Rf = 0.4 in 1:2 v/v ethyl acetate/n-hexane). 
 
1H-NMR (400 MHz, CDCl3) δ 7.33 (s, 1H), 7.09 (s, 1H), 6.06 (s, 2 H), 3.90 (s, 3H).  
13C-NMR (100 MHz, CDCl3) δ 165.7, 151.0, 147.1, 124.4, 115.0, 114.4, 111.0, 102.6, 
52.4. 
These data matched those reported[7] previously. 
 
Methyl 6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzo[d][1,3]dioxole-5-carboxylate 
(140) 
  
 
 
Following the method of Jones,[8] a magnetically stirred mixture of ester 146 (5.00 g, 19.3 
mmol) and anhydrous potassium acetate (6.25 g, 61.7 mmol, 3.2 mol equiv.) in degassed 
acetonitrile (100 mL) was treated with PdCl2(dppf)CH2Cl2 (820 mg, 1.0 mmol, 0.05 mol 
equiv.). The resulting mixture was heated under reflux while being treated, in 5 mL 
portions over 1 h, with a solution of bis(neopentylglycolato)diboron (6.80 g, 30.1 mmol, 
1.5 mol equiv.) in acetonitrile (100 mL). The resulting solution was stirred under reflux 
for another 2 h then cooled, diluted with ethyl acetate (200 mL) and filtered through a 
short plug of CeliteTM. The filtrate was concentrated under reduced pressure to give a 
light-yellow oil that was subjected to flash chromatography (silica gel, 1:4 v/v ethyl 
acetate/n-hexane elution). Concentration of the relevant fractions (Rf = 0.3 in 1:4 v/v ethyl 
acetate/n-hexane) under reduced pressure gave compound 140[8] (5.10 g, 91%) as a low-
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melting, white, crystalline solid. 
 
1H-NMR (400 MHz, CDCl3) δ 7.36 (1H, s), 6.89 (1H, s), 6.00 (2H, s), 3.89 (3H, s), 3.79 
(4H, s), 1.10 (6H, s).  
13C-NMR (100 MHz, CDCl3) δ 168.6, 151.3, 147.9, 135.6, 126.7, 110.6, 109.1, 101.7, 
72.7, 52.6, 31.9, 22.2. 
These data matched those reported[8] previously. 
 
Methyl (3aR,6S,7aS)-6-(cyanomethyl)-2,2-dimethyl-3a,6,7,7a-tetrahydro-{4,5'-bibenzo 
[d][1,3]diox-ole}-6'-carboxylate (147) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of bromide 139 (3.00 g, 
11.0 mmol) in degassed THF/H2O (120 mL of a 9:1 v/v mixture) maintained under a 
nitrogen atmosphere was treated, successively, with boronate ester 140 (4.50 g, 15.4 
mmol, 1.4 mol equiv.), TEA (15 mL, 110 mmol, 10.0 mol equiv.) and 
PdCl2(dppf)CH2Cl2 (800 mg, 0.98 mmol, 0.09 mol equiv.). The resulting mixture was 
heated under reflux for 2 h before being cooled and diluted with ethyl acetate (30 mL) 
then washed with H2O (2 × 60 mL) and brine (1 × 50 mL). The separated organic phases 
were then dried (Na2SO4), filtered and concentrated under reduced pressure to yield a 
brown powder. Flash chromatography (silica gel, 1:2 to 1:1 v/v ethyl acetate/n-hexane 
gradient elution) and concentration of the relevant fractions (Rf = 0.5 in 1:1 v/v ethyl 
acetate/n-hexane) under reduced pressure gave acetonide 147[5] (3.50 g, 86%) as a golden 
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foam. 
 
1H-NMR (CDCl3, 400 MHz) δ 7.41 (s, 1H), 6.70 (s, 1H), 6.03 (d, J = 1.4 Hz, 1H), 6.01 
(d, J = 1.4 Hz, 1H), 5.50 (t, J = 1.6 Hz, 1H), 4.82 (dd, J = 6.0 and 1.6 Hz, 1H), 4.61 (m, 
1H), 3.79 (s, 3H), 2.85 (m, 1H), 2.43-2.40 (complex m, 2H), 2.30 (d, J = 12.0 Hz, 1H), 
1.75 (ddd, J = 13.9, 11.1 and 2.3 Hz, 1H), 1.46 (s, 3H), 1.34 (s, 3H). 
13C-NMR (CDCl3, 100 MHz) δ 166.3, 150.7, 147.1, 141.9, 138.7, 127.4, 122.0, 118.3, 
111.8, 110.4, 108.9, 102.1, 74.6, 72.8, 52.0, 32.0, 28.0, 27.6, 26.1, 23.4. 
These data matched those reported[5] previously. 
 
2-{(2S,4S,4aR)-4-Hydroxy-6-oxo-3,4,4a,6-tetrahydro-2H-[1,3]dioxolo[4',5':4,5]benzo 
[1,2c]chromen-2-yl}acetonitrile (148) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of carboxylate 147 (1.20 
g, 3.23 mmol) in AcOH/H2O (50 mL of a 4:1 v/v mixture) maintained under a nitrogen 
atmosphere at 50 °C for 18 h was allowed to cool to 22 °C then quenched with sodium 
bicarbonate (50 mL of a saturated aqueous solution) and extracted with dichloromethane 
(3 × 50 mL). The combined organic phases were then dried (Na2SO4), filtered and 
concentrated under reduced pressure to yield a yellow oil. Trituration of this material 
(dichloromethane) gave lactone 148[5] (860 mg, 89%) as a white, crystalline solid. 
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1H-NMR (CDCl3, 400 MHz) δ 7.46 (s, 1H), 6.96 (s, 1H), 6.07 (d, J = 4.9 Hz, 2H), 5.08 
(m, 1H), 5.50 (t, J = 1.6 Hz, 1H), 4.46 (m, 1H), 3.47 (s, 1H), 3.18 (m, 1H), 3.21-3.16 
(complex m, 1H), 2.65-2.44 (complex m, 2H), 2.36-2.31 (complex m, 1H), 1.65-1.57 
(complex m, 1H). 
13C-NMR (CDCl3, 100 MHz) δ 163.8, 153.3, 148.9, 133.0, 128.1, 126.7, 117.8, 117.4, 
109.1, 102.6, 102.4, 76.5, 65.0, 32.3, 29.3, 23.5. 
These data matched those reported[5] previously. 
 
2-{(2S,4S,4aR)-4-[(tert-Butyldiphenylsilyl)oxy]-6-oxo-3,4,4a,6-tetrahydro-2H-[1,3] 
dioxolo[4',5':4,5]benzo[1,2-c]chromen-2-yl}acetonitrile (149) 
 
 
 
Following the method of White,[5] a magnetically stirred suspension of alcohol 148 (1.22 
g, 4.1 mmol) in DMF/dichloromethane (30 mL of a 1:1 v/v mixture) maintained under 
nitrogen at 22 °C was treated with imidazole (1.11 g, 16.3 mmol, 4.0 mol equiv.) and tert-
butyldiphenylchlorosilane (3.2 mL, 12.2 mmol, 3.0 mol equiv.). The resulting mixture 
was stirred at this temperature for 12 h before being quenched with sodium bicarbonate 
(20 mL of a half-saturated aqueous solution) and the aqueous phase extracted with ethyl 
acetate (3 × 20 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated under reduced pressure to yield a yellow oil. Flash chromatography (silica 
gel, 1:3 to 1:2 v/v ethyl acetate/n-hexane gradient elution) and concentration of the 
relevant fractions (Rf = 0.8 in 1:2 v/v ethyl acetate/n-hexane) under reduced pressure gave 
ether 149[5] (2.00 g, 90%) as a white foam. 
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1H-NMR (CDCl3, 400 MHz) δ 7.76-7.72 (complex m, 4H), 7.48 (s, 1H), 7.43-7.32 
(complex m, 6H), 7.03 (s, 1H), 6.23 (m, 1H), 6.07 (s, 2H), 4.99 (dd, J = 3.5 and 2.6 Hz, 
1H), 4.49 (t, J = 3.5 Hz, 1H), 3.18 (m, 1H), 2.48 (dd, J = 16.8 and 7.1 Hz, 1H), 2.37 (dd, 
J = 16.3 and 7.1 Hz, 1H), 1.89 (m, 1H), 1.39 (m, 1H), 1.05 (s, 9H). 
13C-NMR (CDCl3, 100 MHz) δ 163.0, 153.0, 148.8, 136.4, 136.1, 134.0, 133.1, 132.4, 
130.0, 129.8, 128.9, 127.9, 125.1, 118.1, 117.8, 109.2, 102.4, 102.3, 76.6, 76.3, 33.7, 30.2, 
27.1, 23.5, 19.6. 
These data matched those reported[5] previously. 
 
(2S,4S,4aR)-2-(2-Aminoethyl)-4-[(tert-butyldiphenylsilyl)oxy]-4,4a-dihydro-2H-[1,3] 
dioxolo[4',5':4,5]benzo[1,2-c]chromen-6(3H)-one (138) 
 
 
 
Following the method of White,[5] a magnetically stirred solution of nitrile 149 (1.74 g, 
3.2 mmol) and Raney-cobalt (3.50 g, 200% w/w) in ammonia-saturated methanol (40 mL) 
was maintained under an atmosphere of hydrogen at 22 °C for 18 h. The reaction mixture 
was then filtered through a pad of CeliteTM and the residual Raney-cobalt washed with 
methanol (3 × 20 mL) and dichloromethane (3 × 20 mL). The combined filtrates were 
concentrated under reduced pressure to afford a brown oil. Flash chromatography (silica 
gel, 3% to 5% v/v ammonia-saturated methanol/dichloro-methane gradient elution) and 
concentration of the relevant fractions (Rf = 0.3 in 5% v/v ammonia-saturated 
methanol/dichloromethane) under reduced pressure gave 1º-amine 138[5] (1.6 g, 92%) as 
a white foam. 
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1H-NMR (CDCl3, 400MHz) δ 7.77-7.74 (complex m, 4H), 7.47 (s, 1H), 7.44-7.35 
(complex m, 6H), 6.98 (s, 1H), 6.24 (s, 1H), 6.01 (s, 2H), 4.94 (m, 1H), 4.45 (t, J = 3.8 
Hz, 1H), 2.85 (m, 1H), 2.68 (m, 2H), 1.76 (m, 1H), 1.63 (m, 1H), 1.41 (m, 1H), 1.25-1.10 
(complex m, 3H), 1.04 (s, 9H). 
13C-NMR (CDCl3, 100 MHz) δ 163.5, 152.6, 147.9, 136.2, 135.9, 134.2, 133.4, 133.2, 
130.3, 129.7, 129.6, 127.5, 127.3, 125.3, 117.2, 108.7, 102.0, 101.9, 77.1, 67.3, 39.2, 39.1, 
33.5, 30.1, 26.9, 19.3. 
These data matched those reported[5] previously. 
 
(3aS,5S,5aR,12bR,12cS)-5-[(tert-Butyldiphenylsilyl)oxy]-1,2,3,3a,4,5,5a,12c-octahydro 
-[1,3]dioxolo[4',5':6,7]isochromeno[3,4-g]indol-7(12bH)-one (151) 
 
 
 
A magnetically stirred solution of amine 138 (530 mg, 0.98 mmol) in degassed benzene 
(240 ml) maintained at 0 °C under a nitrogen atmosphere was treated, in portions, with 
NCS (140 mg, 1.05 mmol, 1.1 mol equiv.). The resulting mixture was warmed to 22 °C 
and stirred at this temperature for 0.5 h before being placed in an oil bath and heated at 
80 °C then treated with AIBN (3.5 mg, 0.02 mmol, 0.02 mol equiv.), followed by a 
solution of tri-n-butyltin hydride (303 µL, 1.13 mmol, 1.15 mol equiv.) in benzene (5 mL) 
that was delivered via syringe pump over 2 h. After a further 4 h the ensuing mixture was 
cooled to 22 °C then concentrated under reduced pressure to give an orange oil. Flash 
chromatography (silica gel, 2% to 5% v/v ammonia-saturated methanol/dichloromethane 
gradient elution) and concentration of the relevant fractions (Rf = 0.4 in 2% v/v ammonia-
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saturated methanol/dichloromethane) under reduced pressure gave compound 151 (325 
mg, 65%) as a white foam.  
 
Optical rotation [α]D20 –0.17° (c 3.24, CDCl3). 
HRMS (ESI, +ve) calcd for C32H35NO5Si [(M+H)+] 542.2363, found 542.2363. 
1H-NMR (CDCl3, 400 MHz) δ 7.72-7.69 (complex m, 4H), 7.52 (s, 1H), 7.41-7.35 
(complex m, 4H), 6.67 (s, 1H), 6.00 (dd, J = 12.0 and 6.0 Hz, 2H), 4.45 (t, J = 6.0 Hz, 
1H), 3.95 (m, 1H), 3.00-2.93 (complex m, 3H), 2.40 (td, J = 12.0 and 4.0 Hz, 1H), 2.20-
2.17 (complex m, 2H), 1.80 (dd, J = 13.6 and 4.4 Hz, 1H), 1.71-1.62 (complex m, 2H), 
1.25 (m, 1H), 1.07 (s, 9H). 
13C-NMR (100 MHz, CDCl3) δ 165.3, 151.6, 147.4, 140.2, 135.8, 135.8, 133.8, 133.8, 
129.8, 127.6(9), 127.6(6), 118.3, 109.9, 107.8, 101.8, 80.1, 67.8, 60.3, 44.3, 40.5, 39.4, 
28.8, 28.2, 26.9, 19.2. 
IR νmax (KBr) 3072, 3046, 2931, 2857, 1716, 1616, 1503, 1480, 1448, 1427, 1386, 1289, 
1258, 1111, 1036, 939, 856, 822, 741, 703 cm−1. 
LRMS (ESI, +ve) m/z 543 (40%), 542 [(M + H)+, 100%]. 
 
(3aS,5S,5aR,12bR,12cS)-5-Hydroxy-1,2,3,3a,4,5,5a,12c-octahydro-[1,3]dioxolo[4',5':6, 
7]isochromeno[3,4-g]indol-7(12bH)-one (137) 
 
 
 
A magnetically stirred solution of compound 151 (500 mg, 0.92 mmol) in THF (20 mL) 
maintained under an atmosphere of nitrogen was cooled to 0 °C then treated with tetra-n-
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butylammonium fluoride (1.84 mL of a 1.0 M solution in THF, 1.84 mmol, 2.0 mol 
equiv.). The resulting mixture was warmed to 22 °C, stirred at this temperature for 12 h 
then quenched with sodium bicarbonate (5 mL of a saturated aqueous solution) and 
extracted with dichloromethane (5 × 10 mL). The combined organic extracts were washed 
with brine (3 × 10 mL) before being dried (Na2SO4), filtered and concentrated under 
reduced pressure to afford a light-yellow oil. Flash chromatography (silica gel, 4% to 8% 
v/v ammonia-saturated methanol/dichloromethane gradient elution) and concentration of 
the relevant fractions (Rf = 0.4 in 8% v/v ammonia-saturated methanol/dichloromethane) 
under reduced pressure gave compound 137 (260 mg, 93%) as a white, crystalline solid. 
 
m.p. 82-83 °C. 
Optical rotation [α]D20 +1.10° (c 1.67, CDCl3).  
HRMS (ESI, +ve) calcd for C16H17NO5 [(M+H)+] 304.1185, found 304.1185. 
1H-NMR (400 MHz, CDCl3) δ 7.52 (s, 1H), 6.83 (s, 1H), 6.04 (dd, J = 9.6 and 1.2 Hz, 
2H), 4.65 (t, J = 2.8 Hz, 1H), 3.99 (m, 1H), 3.12 (m, 1H), 3.04 (m, 1H), 2.50 (dd, J = 10.0 
and 2.4 Hz, 1H), 2.33 (m, 1H), 2.17-2.14 (complex m, 2H), 2.01-1.93 (complex m, 2H), 
1.80-1.70 (complex m, 3H). 
13C-NMR (100 MHz, CDCl3) δ 164.9, 152.2, 147.7, 140.4, 118.0, 110.0, 108.3, 102.1, 
80.1, 66.2, 60.4, 44.5, 40.4, 39.8, 29.5, 28.4.  
IR νmax (KBr) 3340, 2924, 1699, 1616, 1502, 1480, 1449, 1427, 1386, 1289, 1254, 1110, 
1086, 1036, 938, 731 cm−1. 
LRMS (ESI, +ve) m/z 345 (90%), 304 [(M + H)+, 100%]. 
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(1R,2S,3aS,3a'S,12bR)-1,2-Dihydroxy-3,3a,3a',4,5,12b-hexahydro-1H-[1,3]dioxolo[4,5-
j]pyrrolo [3,2,1-de]phenanthridin-7(2H)-one (154) 
 
 
 
A magnetically stirred solution of alcohol 137 (200 mg, 0.66 mmol) in methanol (15 ml) 
maintained under a nitrogen atmosphere at 22 °C was treated with sodium methoxide (71 
mg, 1.32 mmol, 2.0 mol equiv.). The resulting mixture was stirred at 50 °C for 4 h before 
being concentrated under reduced pressure to afford a colorless oil. Flash 
chromatography (silica gel, 4% to 10% v/v ammonia-saturated methanol/dichlorome-
thane gradient elution) and concentration of the relevant fractions (Rf = 0.4 in 8% v/v 
ammonia-saturated methanol/dichloromethane) under reduced pressure gave compound 
154 (176 mg, 88%) as a white, crystalline solid.  
 
m.p. 170-172 °C. 
Optical rotation [α]D20 +1.27° (c 0.30, CH3OH). 
HRMS (ESI, +ve) calcd for C16H18NO5 [(M+H)+] 304.1185, found 304.1186. 
1H-NMR (400 MHz, CD3OD) δ 7.25 (s, 1H), 6.92 (s, 1H), 6.01 (dd, J = 5.2 and 1.2 Hz, 
2H), 4.58 (s, 1H), 4.34 (t, J = 2.4 Hz, 1H), 4.00 (m, 1H), 3.89-3.81 (complex m, 2H), 2.79 
(d, J = 12.8 Hz, 1H), 2.69 (m, 1H), 2.11 (m, 1H), 2.00-1.88 (complex m, 3H). 
13C-NMR (100 MHz, CD3OD) δ 165.8, 152.2, 147.9, 137.6, 126.2, 108.8, 105.6, 103.1, 
69.8, 68.6, 58.3, 47.9, 43.6, 37.8, 31.0, 28.7. 
IR νmax (KBr) 3379, 2923, 1633, 1598, 1462, 1414, 1390, 1267, 1055, 1034, 928, 665 
cm−1.  
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LRMS (ESI, +ve) m/z 326 [(M + Na)+, 15%], 304 [(M + H)+, 60%]. 
 
(1R,3aS,3a'S,12bR)-1-Hydroxy-3,3a,4,5-tetrahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2, 
1de] phenanthridine-2,7(3a'H,12bH)-dione (155) 
 
 
 
A magnetically stirred solution of p-TsOHH2O (310 mg, 1.64 mmol, 2.0 mol equiv.) 
and 4-AcNH-TEMPO (370 mg, 1.72 mmol, 2.1 mol equiv.) in dichloromethane (20 mL) 
was maintained at 22 °C for 0.5 h and the resulting suspension added, in portions, to a 
magnetically stirred solution of diol 154 (250 mg, 0.82 mmol) in dichloromethane (20 ml) 
maintained at 0 °C under an atmosphere of nitrogen. The resulting mixture was warmed 
to 22 °C over 6 h before being quenched with sodium bicarbonate (5 mL of a saturated 
aqueous solution) and extracted with dichloromethane (5 × 10 mL). The combined 
organic phases were dried (Na2SO4), filtered and concentrated under reduced pressure to 
afford a light-yellow oil. Flash chromatography (silica gel, 1% to 2% v/v ammonia-
saturated methanol/dichloromethane gradient elution) and concentration of the relevant 
fractions (Rf = 0.4 in 5% v/v ammonia-saturated methanol/dichloromethane) under 
reduced pressure gave compound 155 (176 mg, 78%) as a white, crystalline solid.  
 
m.p. 129-131 °C. 
Optical rotation [α]D20 +0.57° (c 0.095, CH2Cl2). 
HRMS (ESI, +ve) calcd for C16H16NO5 [(M+H)+] 302.1028, found 302.1028. 
1H-NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 6.88 (s, 1H), 6.00 (dd, J = 10.8 and 1.2 Hz, 
155
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2H), 4.49 (d, J = 4.8 Hz, 1H), 4.26 (dd, J = 12.4 and 7.6 Hz, 1H), 4.02 (dd, J = 13.6 and 
9.2 Hz, 1H), 3.56 (dd, J = 14.4 and 4.8 Hz, 1H), 3.33-3.20 (complex m, 2H), 2.84-2.71 
(complex m, 2H), 2.63 (dd, J = 12.0 and 9.6 Hz, 1H), 2.35 (m, 1H), 1.76 (m, 1H). 
13C-NMR (100 MHz, CDCl3) δ 212.2, 150.7, 147.2, 131.7, 124.9, 108.7, 106.3, 101.8, 
69.2, 54.3, 53.6, 45.3, 42.4, 40.1, 37.4, 33.3. 
IR νmax (KBr) 3401, 2918, 1635, 1600, 1464, 1417, 1263, 1103, 1036, 932, 812 cm−1. 
LRMS (ESI, +ve) m/z 302 [(M + H)+, 100%]. 
 
(1R,3aS,3a'S,12bR)-2,7-Dioxo-2,3,3a,3a',4,5,7,12b-octahydro-1H-[1,3]dioxolo[4,5-j] 
pyrrolo[3,2,1-de]phenanthridin-1-yl benzoate (156) 
 
 
 
A magnetically stirred solution of alcohol 155 (150 mg, 0.5 mmol) in dichloromethane 
(10 mL) maintained under a nitrogen atmosphere at 0 °C was treated with TEA (104 µL, 
0.75 mmol, 1.5 mol equiv.), DMAP (90 mg, 0.75 mmol, 1.5 mol equiv.) and benzoyl 
chloride (120 µL, 1.0 mmol, 2.0 mol equiv.). The resulting mixture was warmed to 22 °C 
and stirred at this temperature for 18 h before being quenched with sodium bicarbonate 
(5 mL of a saturated aqueous solution) and extracted with dichloromethane (3 × 15 mL). 
The combined organic phases were dried (Na2SO4), filtered and concentrated under 
reduced pressure to afford a light-yellow oil. Flash chromatography (silica gel, 1:3 to 1:1 
v/v ethyl acetate/n-hexane gradient elution) and concentration of the relevant fractions 
(Rf = 0.3 in 1:1 v/v ethyl acetate/n-hexane) under reduced pressure gave compound 156 
(82 mg, 73%) as a white, crystalline solid.  
156
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m.p. 109-110 °C.  
Optical rotation [α]D20 +3.37° (c 0.75, CDCl3). 
HRMS (ESI, +ve) calcd for C23H20NO6 [(M+H)+] 406.1291, found 406.1295. 
1H-NMR (400 MHz, CDCl3) δ 7.94-7.92(complex m, 2H), 7.58-7.52 (complex m, 2H), 
7.42-7.38 (complex m, 2H), 6.64 (s, 1H), 6.01 (d, J = 4.0 Hz, 1H), 5.94 (dd, J = 13.6 and 
1.2 Hz, 2H), 4.32-4.24 (complex m, 2H), 3.75 (dd, J = 14.0 and 4.4 Hz, 1H), 3.32 (td, J 
= 12 and 5.6 Hz, 1H), 2.95-2.88 (complex m, 2H), 2.65 (td, J = 12.4 and 4.0 Hz, 1H), 
2.37 (m, 1H), 1.82 (m, 1H).  
13C-NMR (100 MHz, CDCl3) δ 204.8, 165.9, 161.8, 151.0, 147.4, 133.8, 131.1, 130.1, 
128.9, 128.6, 125.0, 109.0, 104.6, 101.9, 69.6, 55.3, 45.4, 41.8, 41.6, 36.7, 33.1. 
IR νmax (KBr) 3306, 2974, 2918, 1732, 1645, 1635, 1461, 1416, 1366, 1263, 1106, 1037, 
933, 709 cm−1. 
LRMS (ESI, +ve) m/z 428 [(M + Na)+, 20%], 406 [(M + H)+, 100%]. 
 
(1R,3a'R,12bR)-2,7-Dioxo-2,3a',4,5,7,12b-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo 
[3,2,1-de] phenanthridin-1-yl benzoate (157) 
 
 
 
A magnetically stirred solution of ketone 156 (80 mg, 0.2 mmol) in anhydrous 
dichloromethane (2 mL) maintained under a nitrogen atmosphere at 0 °C was treated with 
TEA (333 µL, 2.4 mmol, 12.0 mol equiv.) and TMSOTf (362 µL, 2.0 mmol, 10.0 mol 
equiv.). The resulting mixture was stirred at 22 °C for 2 h before being quenched with 
sodium bicarbonate (5 mL of a saturated aqueous solution) and extracted with diethyl 
157
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ether (3 × 15 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford a light-yellow oil. A solution of this oil in 
dichloromethane (2 mL) was treated with a solution of PhSeCl (115 mg, 0.6 mmol, 3.0 
mol equiv.) in dichloromethane (2 mL) at 0 °C and the ensuing mixture stirred at this 
temperature for 1 h before being quenched with sodium bicarbonate (5 mL of a saturated 
aqueous solution) and extracted with ethyl acetate (3 × 15 mL). The combined organic 
phases were washed with brine (3 × 10 mL) then dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford a yellow oil. Flash chromatography (silica 
gel, 1:1 v/v ethyl acetate/n-hexane elution) and concentration of the appropriate fractions 
(Rf = 0.8 in 1:1 v/v ethyl acetate/n-hexane) under reduced pressure gave a white 
amorphous that was dissolved in THF/H2O (3 mL of a 1:1 v/v mixture). NaIO4 (65 mg, 
0.3 mmol, 1.5 mol equiv.) was added to the resulting solution at 0 °C that was then 
allowed to warm to 22 °C as stirred at this temperature for a further 15 h before being 
quenched with sodium bicarbonate (5 mL of a saturated aqueous solution) and extracted 
with ethyl acetate (3 × 15 mL). The combined organic phases were dried (Na2SO4), 
filtered and concentrated under reduced pressure to yield a brown oil. Flash 
chromatography (silica gel, 3% v/v ammonia-saturated methanol/dichloromethane 
elution) and concentration of the relevant fractions (Rf = 0.5 in 3% v/v ammonia-saturated 
methanol/dichloromethane) under reduced pressure gave enone 157 (50 mg, 62%) as a 
white, crystalline solid.  
 
HRMS (ESI, +ve) calcd for C23H17NO6 [(M+H)+] 404.1135, found 404.1134. 
1H-NMR (400 MHz, CDCl3) δ 7.94-7.89(complex m, 2H), 7.57 (s, 1H), 7.54 (m, 1H), 
7.43-7.38 (complex m, 2H), 6.82 (s, 1H), 6.29 (d, J = 2.9 Hz, 1H), 6.13 (s, 1H), 6.00-5.96 
(complex m, 2H), 5.13 (m, 1H), 4.82 (d, J = 12.0 Hz, 1H), 4.05 (m, 1H), 3.95 (m, 1H), 
3.55 (dd, J = 12.0 and 2.9 Hz, 1H), 3.12 (m, 1H). 
Chapter Five 
_________________________________________________________________________________________________________________________________________________________________________ 
 129 
LRMS (ESI, +ve) m/z 426 [(M + Na)+, 100%], 404 [(M + H)+, 97%]. 
 
5.4 Experimental Procedures Related to Work Described in Chapter Four 
 
(3aS,5S,12cS)-5-[(tert-Butyldiphenylsilyl)oxy]-1,3,3a,4,5,12c-hexahydro-[1,3]dioxolo 
[4',5':6,7]isochromeno[3,4-g]indol-7(2H)-one (150) 
 
 
 
A magnetically stirred solution of amine 138 (300 mg, 0.55 mmol) in degassed benzene 
(20 mL) maintained at 22 °C under an atmosphere of nitrogen was treated, in portions, 
with NBS (108 mg, 0.61 mmol, 1.1 mol equiv.). The resulting mixture was stirred at this 
temperature for 0.5 h before being placed in an oil bath and heated at 85 °C then treated 
with AIBN (11.5 mg, 0.07 mmol, 0.13 mol equiv.), followed by a solution of tri-n-butyltin 
hydride (194 µL, 0.72 mmol, 1.3 mol equiv.) in benzene (5 mL) that was delivered via 
syringe pump over 0.83 h. After a further 2 h the resulting mixture was cooled to 22 °C 
then concentrated under reduced pressure to give an orange oil. Flash chromatography 
(silica gel, 2% to 5% v/v ammonia-saturated methanol/dichloromethane gradient elution) 
and concentration of the relevant fractions (Rf = 0.4 in 2% v/v ammonia-saturated 
methanol/dichloromethane) under reduced pressure gave compound 150 (246 mg, 83%) 
as a white foam. 
 
Optical rotation [α]D20 –3.95º (c 1.0, CHCl3). 
HRMS (ESI, +ve) calcd for C32H33NO5Si [(M+H)+] 540.2206, found 540.2206. 
150
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1H-NMR (400 MHz, CDCl3) δ 7.75-7.65 (complex m, 4H), 7.48-7.21 (complex m, 8H), 
6.04 (m, 2H), 4.42 (t, J = 3.0 Hz, 1H), 3.96 (d, J = 6.0 Hz, 1H), 3.20 (m, 1H), 3.05 (m, 
1H), 2.88 (m, 1H), 2.19 (m, 1H), 1.71 (m, 1H), 1.53 (m, 2H), 1.06 (s, 9H) (signal due to 
N–H group proton was not observed). 
13C-NMR (100 MHz, CDCl3) δ 160.9 153.7 151.9 148.2 135.9(1), 135.8(7), 134.8, 133.8, 
133.2, 129.7(1), 129.6(5), 127.7, 127.5, 116.3, 111.2, 107.3, 103.5, 102.2, 66.7, 56.6, 
46.2, 33.7, 32.7, 31.4, 27.0, 19.4.  
IR νmax (KBr) 2929, 2856, 1716, 1503, 1482, 1416, 1254, 1111, 1070, 1035, 937 cm−1. 
LRMS (ESI, +ve) m/z 562 [(M + Na)+, 6%], 540 [(M + H)+, 50%], 267 (100%). 
 
(3aS,5S,12cS)-5-Hydroxy-1,3,3a,4,5,12c-hexahydro-[1,3]dioxolo[4',5':6,7]isochromeno 
[3,4-g]indol-7(2H)-one (176) 
 
 
 
A magnetically stirred solution of compound 150 (215 mg, 0.4 mmol) in THF (40 mL) 
maintained under an atmosphere of nitrogen was cooled to 0 °C then treated with tetra-n-
butylammonium fluoride (0.8 mL of a 1.0 M solution in THF, 0.8 mmol, 2.0 mol equiv.). 
The resulting mixture was warmed to 22 °C, stirred at this temperature for 18 h then 
quenched with sodium bicarbonate (5 mL of a saturated aqueous solution) and extracted 
with dichloromethane (3 × 10 mL). The combined organic phases were washed with brine 
(3 × 10 mL) before being dried (Na2SO4), filtered and concentrated under reduced 
pressure to afford a light-yellow oil. Flash chromatography (silica gel, 4% v/v ammonia-
saturated methanol/dichloromethane elution) and concentration of the relevant fractions 
176
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(Rf = 0.4 in 4% v/v ammonia-saturated methanol/ dichloromethane) under reduced 
pressure gave compound 176 (114 mg, 95%) as a white, crystalline solid. 
 
m.p. 163-164 °C. 
Optical rotation [α]D20 +82.5º (c 1.0, CHCl3).  
HRMS (ESI, +ve) calcd for C16H15NO5 [(M+H)+] 302.1028, found 302.1027. 
1H-NMR (400 MHz, CDCl3) δ 7.33 (s, 1H), 7.17 (s, 1H), 6.06 (s, 1H), 6.03 (s, 1H), 4.43 
(s, 1H), 3.76 (d, J = 6.0 Hz, 1H), 3.25 (m, 1H), 3.01 (m, 1H), 2.69 (m, 1H), 2.13 (m, 1H), 
1.90-1.71 (complex m, 2H), 1.59 (m, 1H) (signals due to N–H and O–H group protons 
were not observed). 
13C-NMR (100 MHz, CDCl3) δ 161.3, 153.7, 152.3, 148.1, 134.6, 115.6, 110.9, 107.1, 
103.3, 102.3, 64.3, 56.4, 46.1, 32.7, 32.5, 31.2.  
IR νmax (KBr) 3416, 3330, 2927, 1706, 1654, 1502, 1483, 1418, 1282, 1255, 1115, 1037 
cm−1.  
LRMS (ESI, +ve) m/z 324 [(M + Na)+, 13%], 302 [(M + H)+, 22%], 267 (100%). 
 
(3aS,12cS)-1,2,3,3a,4,12c-Hexahydro-[1,3]dioxolo[4',5':6,7]isochromeno[3,4-g]indole-
5,7-dione (179) 
 
 
 
A magnetically stirred solution of alcohol 176 (105 mg, 0.35 mmol) in dichloromethane 
(25 mL) maintained under a nitrogen atmosphere was treated, in portions, with 
manganese dioxide (455 mg, 5.2 mmol, 15.0 mol equiv.). The resulting mixture was 
179
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heated at 30 °C for 22 h then cooled to 22 °C before being filtered through a pad of 
Celite™. The filtrate was concentrated under reduced pressure to give a brown oil that 
was subjected to flash chromatography (silica gel, 2% to 3% v/v ammonia-saturated 
methanol /dichloromethane gradient elution) and concentration of the relevant fractions 
(Rf = 0.5 in 3% v/v ammonia-saturated methanol/dichloromethane) under reduced 
pressure gave compound 179 (81 mg, 78%) as a white solid. 
 
m.p. 142-143 °C.  
Optical rotation [α]D20 +88.8º (c 1.0, CDCl3). 
HRMS (ESI, +ve) calcd for C16H13NO5 [(M+H)+] 300.0872, found 300.0871. 
1H-NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.42 (s, 1H), 6.16 (m, 2H), 4.30 (d, J = 4.0 
Hz, 1H), 3.32 (m, 1H), 3.15 (m, 1H), 2.90 (m, 1H), 2.73-2.62 (complex m, 2H), 2.20 (m, 
1H), 1.84 (br s, 1H), 1.71 (m, 1H). 
13C-NMR (100 MHz, CDCl3) δ 188.7, 159.3, 153.9, 150.5, 143.1, 132.5, 124.6, 119.3, 
108.3, 104.7, 102.8, 56.0, 46.2, 39.3, 37.4, 31.5. 
IR νmax (KBr) 3349, 2931, 2876, 1714, 1677, 1501, 1484, 1416, 1322, 1274, 1254, 1145, 
1026 cm−1. 
LRMS (ESI, +ve) m/z 621 [(2M + Na)+, 77%], 599 [(2M + H)+, 99%], 322 [(M + Na)+, 
46%], 300 [(M + H)+, 80%], 283 (100%). 
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(3aS,5R,12cS)-5-Hydroxy-1,3,3a,4,5,12c-hexahydro-[1,3]dioxolo[4',5':6,7]isochromeno 
[3,4-g]indo7 (2H)-one (174) 
 
 
 
A magnetically stirred solution of ketone 179 (73 mg, 0.25 mmol) and CeCl37H2O (92 
mg, 0.38 mmol, 1.5 mol equiv.) in methanol (10 mL) was cooled to –78 °C and, after 
0.25 h, treated with sodium borohydride (11.3 mg, 0.03 mmol, 1.2 mol equiv.) then, after 
0.03 h, with sodium bicarbonate (2 mL of a saturated aqueous solution). The resulting 
mixture was extracted with dichloromethane (5 × 10 mL) and the combined organic 
phases were dried (Na2SO4), filtered and concentrated under reduced pressure to afford a 
light-yellow oil. Flash chromatography (silica gel, 4% v/v ammonia-saturated 
methanol/dichloromethane elution) and concentration of the relevant fractions (Rf = 0.4 
in 4% v/v ammonia-saturated methanol/dichloromethane) under reduced pressure gave 
compound 174 (73 mg, 99%) as a white, crystalline solid. 
 
m.p. 168-169 °C. 
Optical rotation [α]D20 +83.9º (c 1.0, CDCl3). 
HRMS (ESI, +ve) calcd for C16H15NO5 [(M+H)+] 302.1028, found 302.1031. 
1H-NMR (400 MHz, CDCl3) δ 7.57 (s, 1H), 7.34 (s, 1H), 6.10 (m, 2H), 4.65 (dd, J = 12.0 
and 6.0 Hz, 1H), 3.86 (d, J = 3.0 Hz, 1H), 3.32 (m, 1H), 3.05 (m, 1H), 2.43 (m, 1H), 2.15-
2.02 (complex m, 3H), 1.78-1.63 (complex m, 2H) (signal due to N–H group proton was 
not observed). 
174
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13C-NMR (100 MHz, CDCl3) δ 161.3, 154.1, 152.6, 148.2, 135.0, 115.3, 107.4, 103.5, 
102.3, 65.9, 57.1, 46.0, 35.7, 33.1, 31.8 (one signal obscured or overlapping). 
 IR νmax (KBr) 3316, 2926, 2870, 1709, 1621, 1502, 1481, 1416, 1283, 1256, 1165, 1094, 
1034 cm−1. 
 LRMS (ESI, +ve) m/z 324 [(M + Na)+, 40%], 302 [(M + H)+, 100%], 241 (35%). 
 
(3aS,5R,12cS)-5-Methoxy-1-methyl-1,3,3a,4,5,12c-hexahydro-[1,3]dioxolo[4',5':6,7] 
isochromeno[3,4-g]indol-7(2H)-one (ent-29) 
 
 
 
A magnetically stirred solution of alcohol 174 (18.6 mg, 0.06 mmol) in dry THF (2 mL) 
maintained under a nitrogen atmosphere at 0 °C was treated, in portions, with potassium 
hydride (32 mg of a 30% dispersion in mineral oil, 0.24 mmol, 4.0 mol equiv.) then with 
methyl iodide (30 µL, 0.48 mmol, 8.0 mol equiv.). After a further 4 h the reaction mixture 
was quenched with NH4Cl (2 mL of a saturated aqueous solution) and the separated 
aqueous phase extracted with dichloromethane (3 × 10 mL). The combined organic 
phases were dried (Na2SO4), filtered and concentrated under reduced pressure to yield a 
light-yellow oil. Flash chromatography (silica gel, 5% v/v, ammonia-saturated 
methanol/dichloromethane elution) and concentration of the relevant fractions (Rf = 0.4 
in 5% v/v ammonia-saturated methanol/dichloromethane) under reduced pressure gave 
(+)-narseronine (ent-29) (16.8 mg, 83%) as a white, crystalline solid.  
 
 
 ent-29
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m.p. 165-166 °C {lit.[9] for (–)-narseronine 167-168 °C}. 
Optical rotation [α]D20 +21.0º (c 0.3, CHCl3).  
HRMS (ESI, +ve) calcd for C18H19NO5 [(M+H)+] 330.1341, found 330.1342. 
1H-NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.28 (s, 1H), 6.13 (m, 2H), 4.22 (t, J = 6.0 
Hz, 1H), 3.82 (br s, 1H), 3.57 (s, 3H), 3.07 (m, 1H), 2.78 (m, 1H), 2.64 (m, 1H), 2.44 (s, 
3H), 2.25-2.10 (complex m, 2H), 2.01 (m, 1H), 1.90 (m, 1H). 
13C-NMR (100 MHz, CDCl3) δ 161.5, 153.7, 152.7, 148.3, 135.2, 116.4, 108.5, 107.8, 
103.3, 102.4, 75.0, 62.0, 58.2, 54.3, 42.1, 35.0, 31.4, 29.5. 
IR νmax (KBr) 3449, 2927, 1718, 1623, 1502, 1482, 1413, 1282, 1256, 1161, 1102, 1035 
cm−1. 
LRMS (ESI, +ve) m/z 352 [(M + Na)+, 8%], 330 [(M + H)+, 100%], 298 (20%). 
 
(R)-2-[2-(Dimethylamino)ethyl]-4-hydroxy-3H-[1,3]dioxolo[4',5':4,5]benzo[1,2-c] 
chromen-6(4H)-one (182) 
 
 
 
A magnetically stirred mixture of compound 174 (42 mg, 0.14 mmol) and methyl iodide 
(1 mL, 16 mmol, 114.0 mol equiv.) maintained under a nitrogen atmosphere at 22 °C was 
treated with silver(I) oxide (323 mg, 1.4 mmol, 10.0 mol equiv.) and the resulting mixture 
stirred in a sealed tube at 50 °C for 16 h before being cooled, filtered and concentrated 
under reduced pressure. The resulting yellow oil was subjected to flash chromatography 
(silica gel, 5% to 10% ammonia-saturated methanol/dichloromethane gradient elution) 
and concentration of the relevant fractions (Rf = 0.3 in 10% ammonia-saturated methanol/ 
182
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dichloromethane) under reduced pressure gave an unstable oil (30 mg), a portion of which 
crystallised on standing. A crystal of this material was subjected to single-crystal X-ray 
analysis and this revealed it to be the arene hydrate 182. The very small quantities of 
compound 182 obtained by this means precluded the acquisition of any other spectral 
data. 
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Appendix One: Reaction Schemes 
 
A 1.1 Approaches to a Total Synthesis of ent-Kirkamide (ent-57)  
______________________________________________________________________ 
 
Reaction conditions: (a) NBS, THF/H2O (4:1 v/v), 0 to 22 °C, 1 h, 93%; (b) NaH, THF, 0 to 
22 °C, 5 h, 92%; (c) PPh3, p-NO2PhCO2H, DEAD, THF, 0 °C, 4 h, 88%; (d) MeOH (NH3 sat.), 
22 °C, 0.5 h, 93%; (e) i) benzoyl isocyanate, THF, −78 to 0 °C, N2, 1 h; ii) K2CO3, TBAC, 
THF/H2O (10:1 v/v), 22 °C, 2 h; iii) NaOH, MeOH/H2O (1:1 v/v), reflux, 2 h; iv) Ac2O, 
MeOH/H2O (1:1 v/v), 22 °C, 2 h, 82% from 91; (f) CO (1 atm), Pd(OAc)2, PPh3, TEA, 40 °C, 6 
h, 78%.  
______________________________________________________________________ 
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A 1.2 A Chemoenzymatic Approach to (+)-Lycorine (ent-101) 
______________________________________________________________________ 
 
Reaction conditions: (a) NBS, THF/H2O (4:1 v/v), 0 to 22 °C, 4 h; (b) 2,2-DMP, p-TsOH•H2O, 
22 °C, 2 h, 92% over two steps; (c) i) NaH, THF, 0 °C, 0.5 h; ii) acetonitrile, n-BuLi, THF, −78 °C, 
0.25 h, 88%; (d) NaH, CS2, MeI, THF, 0 to 22 °C, 1.5 h, 90%; (e) AIBN, n-Bu3SnH, benzene, 
reflux, 2 h, 87%; (f) Br2, iron powder, AcOH, 22 °C, 72 h, 91%; (g) i) NaClO2, NaH2PO4H2O, 
acetone/H2O (1:1 v/v), 22 °C, 2 h, quantitative; ii) MeOH, H2SO4, reflux, 24 h, 92%; (h) KOAc, 
bis(neopentylglycolato)diboron, PdCl2(dppf)•CH2Cl2, acetonitrile, reflux, 3 h, 91%; (i) TEA, 
PdCl2(dppf)•CH2Cl2, THF/H2O (9:1 v/v), reflux, 2 h, 86%; (j) AcOH/H2O (4:1 v/v), 50 °C, 18 h, 
89%; (k) TBDPS-Cl, imid., DCM, 22 °C, 18 h, 90%; (l) Raney-cobalt, H2 (1 atm), MeOH (NH3 
sat.), 22 °C, 18 h, 92%; (m) i) NCS, benzene, 22 °C, 0.5 h; ii) AIBN, n-Bu3SnH, benzene, 80 °C, 
6 h, 65%; (n) TBAF, THF, 22 °C, 12 h, 93%; (o) NaOMe, MeOH, 50 °C, 4 h, 88%; (p) 4-AcNH-
TEMPO, p-TsOHH2O, DCM, 0 to 22 °C, 3.5 h, 78%; (q) BzCl, TEA, DMAP, DCM, 0 to 22 °C, 
18 h, 73%; (r) i) TMSOTf, TFA, DCM, 0 to 22 °C, 2 h; ii) PhSeCl, DCM, 0 °C, 1 h; iii) NaIO4, 
THF/H2O (1:1 v/v), 22 °C, 15 h, 62% over three steps. 
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A 1.3 An Enantioselective Route to (+)-Narseronine (ent-29) 
______________________________________________________________________ 
 
Reaction conditions: (a) NBS, THF/H2O (4:1 v/v), 0 to 22 °C, 4 h; (b) 2,2-DMP, p-TsOH•H2O, 
22 °C, 2 h, 92% over two steps; (c) i) NaH, THF, 0 °C, 0.5 h; ii) acetonitrile, n-BuLi, THF, −78 °C, 
0.25 h, 88%; (d) NaH, CS2, MeI, THF, 0 to 22 °C 1.5 h, 90%; (e) AIBN, n-Bu3SnH, benzene, 
reflux, 2 h, 87%; (f) Br2, iron powder, AcOH, 22 °C, 72 h, 91%; (g) i) NaClO2, NaH2PO4H2O, 
acetone/H2O (1:1 v/v), 22 °C, 2 h, quantitative; ii) MeOH, H2SO4, reflux, 24 h, 92%; (h) KOAc, 
bis(neopentylglycolato)diboron, PdCl2(dppf)•CH2Cl2, acetonitrile, reflux, 3 h, 91%; (i) TEA, 
PdCl2(dppf)•CH2Cl2, THF/H2O (9:1 v/v), reflux, 2 h, 86%; (j) AcOH/H2O (4:1 v/v), 50 °C, 18 h, 
89%; (k) TBDPS-Cl, imid., DCM, 22 °C, 18 h, 90%; (l) Raney-cobalt, H2 (1 atm), MeOH (NH3 
sat.), 22 °C, 18 h, 92%; (m) i) NBS, benzene, 22 °C, 0.5 h; ii) AIBN, n-Bu3SnH, benzene, 80 °C, 
1.5 h, 83%; (n) TBAF, THF, 22 °C, 18 h, 95%; (o) MnO2, DCM, 30 °C, 22 h, 78%; (p) NaBH4, 
CeCl37H2O, MeOH, −78 °C, 0.3 h, 99%; (q) KH, MeI, THF, 0 to 22 °C, 4 h, 83%. 
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Appendix Two: X-ray Crystallographic Data 
 
A 2.1 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 81 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 81 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 81 
is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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A 2.2 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 82 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 82 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 82 
is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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A 2.3 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 137 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 137 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 
137 is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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A 2.4 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 155 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 155 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 
155 is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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A 2.5 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 176 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 176 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 
176 is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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A 2.6 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 174 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 174 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 
174 is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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A 2.7 ORTEP Derived from the Single-crystal X-ray Analysis of Compound ent-29 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound ent-29 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 
ent-29 is provided in PDF format on the compact disc found on the inside back cover of this 
thesis. 
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A 2.8 ORTEP Derived from the Single-crystal X-ray Analysis of Compound 182 
 
 
 
 
 
 
 
ORTEP derived from the single-crystal X-ray analysis of compound 182 with labeling of non-
hydrogen atoms. Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen 
atoms are drawn as circles with small radii. A full X-ray crystallographic report for compound 
182 is provided in PDF format on the compact disc found on the inside back cover of this thesis. 
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